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Abstract 
 Bacterial pneumonia, one of the leading causes of hospitalization and mortality 
worldwide, is caused by the colonization of invasive bacteria in the airways, leading to 
pulmonary inflammation and lung dysfunction. The development of antibiotic resistant 
bacterial infections has limited the effectiveness of current therapeutics and is particularly 
concerning in the setting of chronic bacterial infections, such as observed in cystic fibrosis 
and ventilator-associated pneumonia. The development of novel therapeutics for the 
treatment of multi-drug resistant bacterial pneumonia is urgently needed. 
 The overall objective of this body of work was the development of a new 
therapeutic compound to treat multi-drug resistant bacterial infections in the lung. It was 
hypothesized that a cathelicidin/exogenous surfactant compound could be developed as a 
novel therapeutic agent for the treatment of bacterial pneumonia. To test this hypothesis, 
we first screened several cathelicidin peptides combined with a commercial exogenous 
surfactant, bovine lipid extract surfactant (BLES), and identified a lead compound (CATH-
2) for further testing. Following this, we investigated three main outcomes: 1) the 
antimicrobial activity of CATH-2 and BLES+CATH-2 against multi-drug resistant, 
clinically isolated bacteria; 2) the immunomodulatory potential of both CATH-2 and 
BLES+CATH-2 in vivo; and 3) the bactericidal activity of BLES+CATH-2 treatment in 
vivo, using two models of bacterial pneumonia. 
 It was discovered that CATH-2 was able to kill bacteria in vitro. In addition, CATH-
2-killed bacteria administered into the lungs of mice did not induce an inflammatory 
response in vivo, and the ability to prevent this inflammation was maintained by 
BLES+CATH-2. Finally, while BLES+CATH-2 is able to kill multi-drug resistant, 
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clinically derived bacteria in vitro, there is little bactericidal activity of BLES+CATH-2 in 
in vivo models of bacterial pneumonia. 
 Overall, we identified the therapeutic potential of BLES+CATH-2 for use as a 
therapeutic treatment for bacterial pneumonia. Despite promising in vitro activity, we were 
unable to show bactericidal activity for BLES+CATH-2 in vivo. Future directions will 
require the optimization of the surfactant-cathelicidin compound in order to develop a 
viable therapeutic for clinical practice. 
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Chapter 1: General Introduction and Literature Review 
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 Every day, approximately 10 000 L of air will flow into and out of the lungs, and 
bring with it foreign particles, such as bacteria, from either the surrounding environment or 
the nasopharynx. Due to the unique branching structure of the lung, some of this 
particulate-filled air will pass into the terminal bronchioles, respiratory bronchioles, and 
alveoli. Over the course of this steady siege, some pathogens are able to circumvent the 
innate immune system, leading to colonization and infection of the lung, known as 
pneumonia. Pneumonia is one of the most common presentations of bacterial infections, 
with millions of people being diagnosed annually (1). It is the leading cause of death due 
to infection; estimates by the World Health Organization suggest that bacterial pneumonia 
is responsible for 15% of all children deaths under the age of 5, and an estimated 3.2 million 
deaths annually (2–5). 
Furthermore, the rate of drug-resistant infections is rapidly escalating, and is 
becoming a large global health concern. Multi-drug resistant infections are currently 
estimated to be responsible for 700 000 deaths per year, with that number expected to rise 
to 10 million per year by 2050 without immediate intervention (6). The high prevalence of 
pneumonia infection and increasing rates of antibiotic resistant infections are two factors 
culminating into a potential global health disaster.  
The purpose of this thesis will be to determine the efficacy of a novel therapeutic 
for the treatment of multi-drug resistant bacterial pneumonia. Here, we investigate the 
development of a potential treatment using a cathelicidin peptide in conjunction with 
exogenous surfactant as a vehicle to improve delivery to the respiratory system. This 
chapter will provide an overview of homeostatic respiratory functions, pathologic 
processes that develop over the course of chronic bacterial respiratory infections in cystic 
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fibrosis or mechanical ventilation, and the morbidities of antibiotic resistance associated 
with these pulmonary infections. Finally, it will provide an overview of both cathelicidins 
and exogenous surfactant, and their therapeutic potential for the treatment of multi-drug 
resistant bacterial pneumonia. 
 
1.1 Lung Structure and Function in Homeostatic Conditions 
The primary function of the lungs is gas exchange. In the lungs, oxygen diffuses 
from the alveoli at the terminal ends of the airways, across epithelia and endothelia, and 
into the deoxygenated blood within the surrounding alveolar capillaries; mirroring this, 
carbon dioxide moves down its concentration gradient from the blood stream into the 
alveoli and is eventually expired out of the body (Reviewed in (7)).   
 The anatomy of the lungs involves a complex branching network, beginning in the 
nasopharynx, to the trachea, and then branching into two primary bronchi.  From there, the 
bronchi will continue to divide into smaller and smaller airways, eventually forming 
terminal bronchioles. These structures are involved in air flow, but do not participate in gas 
exchange. Distal to the terminal bronchioles are respiratory bronchioles, which are 
structurally similar with the exception that they contain budding alveoli that will participate 
in gas exchange. Past these respiratory bronchioles are alveolar sacs, containing groups of 
alveoli, the primary regions of gas exchange. The complex branching structure allows for 
a large surface area at the alveolar level, allowing for rapidly efficient gas exchange with 
the surrounding alveolar capillaries (7). 
 The alveoli themselves are structured by a combination of thin, squamous Type I 
alveolar cells and a smaller number of cuboidal Type II alveolar cells. Type I cells are 
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essential for gas exchange, as their large surface area and thin structure allows for maximal 
diffusion. On the other hand, Type II cells are essential for numerous other functions, 
including replenishing Type I cell populations after injury, and producing pulmonary 
surfactant, a lipoprotein substance that contributes to breathing mechanics (8, 9). Other 
cells within the alveolar space include alveolar macrophages, essential phagocytes tasked 
with patrolling the alveoli, engulfing inhaled pathogens and debris particles, and regulating 
the innate and adaptive immune system (10–12). 
1.1.1 Pulmonary mechanics 
 To facilitate gas exchange, air flows in and out of the lungs by a process known as 
ventilation. This process requires the coordinated contraction of both external intercostal 
muscles and the diaphragm to increase the volume of the thoracic cavity. This increased 
volume causes a decrease in pressure, as predicted by Boyle’s Law, and causes the 
movement of a discrete volume of external air to enter into the lungs, referred to as the tidal 
volume. At rest, exhalation is due to the relaxation of these muscles; the decreased thoracic 
volume then creates a (relatively) high-pressure environment within the lungs, and air 
moves out to the external environment. During exertion, internal intercostals, abdominals, 
and oblique muscles will also contract to reduce thoracic cavity volume with greater force, 
increasing the volume and rate of exhalation (7). 
 In addition to the role of the respiratory muscles, there are numerous other processes 
within the lungs that affect ventilation. One specific measurement of these mechanics is 
lung compliance. Lung compliance refers to the amount of force required to inflate the 
lungs. This is calculated as the volume change per unit of pressure change (7). There are 
two major factors in the lung responsible for compliance – lung elastic tissue, and surface 
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tension within the small airways and alveoli (discussed in section 1.1.2). The elastance of 
the lung is proportional to the structural components of the lungs, specifically the amount 
of elastin and collagen content within the airway interstitium (7). Increased elastin and 
collagen content within the lung leads to reduced compliance, as it increases the force 
required to expand the lungs upon inhalation. The surface tension within the lungs has a 
major effect on lung function, as increased surface tension has a significant impact on lung 
compliance and alveolar stability upon exhalation. Pulmonary surfactant is directly 
responsible for reducing the surface tension within the lung. 
1.1.2 The pulmonary surfactant system 
 As noted above, one of the forces responsible for determining lung compliance is 
surface tension. The surface tension within the lungs is caused by a thin liquid layer lining 
the entire respiratory tract, known as the airway surface liquid (ASL), that begins in the 
nasopharynx and extends down to the alveoli. Within the alveoli, the surface tension 
exerted by water molecules of the ASL produce an elastic force that reduces compliance. 
Pulmonary surfactant is responsible for reducing this force by adsorbing to the air-liquid 
interface of the ASL and acting to reduce surface tension during exhalation and inhalation 
(13, 14). During exhalation, due to the decreasing size of the alveoli, lateral compression 
of the pulmonary surfactant film reduces surface tension to minimal values; this minimizes 
any collapse force on the alveoli (14). By reducing surface tension, the collapse force is 
reduced, making the lungs easier to inflate. Therefore, reducing surface tension is directly 
associated with increased lung compliance. 
Pulmonary surfactant is a lipoprotein complex produced and secreted by type II 
alveolar cells (9). It is found in all mammalian species and has a highly conserved 
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composition (15). It is made up of ~80% lipids by mass, such as phosphatidylcholine (PC, 
80% of lipid subfraction) and phosphatidylglycerol (PG, 10-11% of lipid 
subfraction),~10% neutral lipids, such as cholesterol, and ~10% surfactant associated 
proteins, named SP-A, -B, -C, and -D (16). Upon synthesis of these lipid-protein mixtures, 
type II cells store surfactant in intracellular structures known as lamellar bodies until 
signalled to secrete into the airspace (17, 18). Once secreted, the surfactant will adsorb to 
the air-liquid interface to form a surface-active film, which is further discussed below (19, 
20). The “functional” components of surfactant are experimentally known as the “large 
aggregate”. During repeated cyclic expansions and compressions of the surface film 
(throughout the course of respiration), small surfactant vesicles are generated, and then 
recycled by resident alveolar macrophages and type II cells; this “inactive” surfactant 
component is experimentally referred to as “small aggregate” (21, 22). 
 While true de novo adsorption only occurs during the first breath at birth, surfactant 
secreted into the alveolar liquid lining spreads rapidly along the interface in order to form 
the surface-active film responsible for surface tension reduction upon compression. 
Surfactant-associated proteins SP-B and SP-C promote the breaking of stable phospholipid 
bilayers in the aqueous layer to induce adsorption of lipids to the air-liquid interface. The 
rapid diffusion and spreading of the surfactant film allows for the initial reduction of 
surface tension in the alveoli, improving lung compliance and alveolar stability (19). After 
this first breath, surfactant is cycled into the air-liquid interface over the course of 
respiration with the help of SP-B and SP-C, as inactivated surfactant lipids are recycled 
back to type II cells or degraded by alveolar macrophages (23). 
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Patients with a poorly functioning pulmonary surfactant system, or surfactant 
deficient states, typically exhibit a severe decrease in lung compliance, eventually leading 
to atelectasis (alveolar collapse) and decreased oxygenation. One such example is neonatal 
respiratory distress syndrome (nRDS), where premature infants are born without a fully 
developed pulmonary surfactant system (24). Administration of exogenous surfactant to 
neonates lacking sufficient pulmonary surfactant has been demonstrated to rapidly improve 
compliance, oxygenation, and patient outcomes (25–27). Since its identification as a viable 
therapeutic in the 1980’s, exogenous surfactant administration has become a standard 
treatment for premature infants diagnosed with nRDS (25, 28). Due to its superior clinical 
efficacy and its innate ability to spread throughout the respiratory tract, surfactant has since 
been investigated for numerous other therapeutic functions, such as a vehicle for pulmonary 
therapy distribution (29, 30). 
 
1.2 Chronic Bacterial Lung Infections 
 Bacterial pneumonia is an infection of the respiratory tract, and is one of the leading 
causes of hospitalization (4, 31–34). Over the course of prolonged infection, the continual 
inflammatory environment can precipitate structural changes to the respiratory tract, 
eventually resulting in severe decreases in oxygenation and potentially death (35, 36). 
Chronic infections associated with cystic fibrosis or mechanical ventilation are two major 
examples in which prolonged infections associated with these underlying conditions 
increase the complexity of the disease and increase the rate of mortality (4, 35, 37). Typical 
treatment strategies for these two diseases involve administration of antibiotics to target the 
infection; however, the bacteria are typically incompletely eradicated, and antibiotic use is 
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forced to continue over a prolonged period, or to treat acute exacerbations (38). As such, 
prolonged administration of antibiotics, without the effective clearance of the colonizing 
bacteria, can contribute directly to the high prevalence of antimicrobial resistant infections, 
further complicating treatment strategies.  
1.2.1 Cystic fibrosis 
Cystic fibrosis (CF) is an inherited disease of the cystic fibrosis transmembrane 
conductance regulator (CFTR). The development of this disease has been thoroughly 
investigated since the initial identification of the CFTR gene (39–41). In these patients, a 
non-functioning/hypofunctioning CFTR channel prevents the movement of chloride and 
bicarbonate ions into the air surface liquid. Due to the poor movement of ions across the 
luminal membrane, there is a decrease in osmotic forces into the lumen, and as a result the 
ASL becomes dehydrated and viscous. This highly viscous mucus is unable to properly 
detach from the secretory ducts of submucosal glands after secretion (42). To further 
compound this problem, the cilia on the apical surface of the airway epithelia become less-
functional, meaning that any particles or pathogens trapped in the thickened mucus can no 
longer be cleared from the airways. These individual factors combine to elicit the bacteria-
laden mucus plugs characteristic of cystic fibrosis pulmonary disease (43). Combined with 
the defect in the mucociliary escalator, studies have also shown that there is a severe 
detriment in the innate host defense of recruited cell types as well (44). Decreases in the 
pH of the ASL, likely due to the reduction of bicarbonate movement, has been 
demonstrated to be responsible for lack of bacterial killing induced by the innate factors 
present, including cathelicidins, defensins, and other antimicrobial peptides (44). 
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Interestingly, this acidified environment also appears to have an effect on the viscosity of 
the ASL itself (45). 
The result of these deficiencies allows pathogens to colonize and proliferate, and 
without a functioning clearance system, CF patients develop frequent, spontaneous lung 
infections of Staphylococcus aureus, Pseudomonas aeruginosa, Achromobacter 
xylosoxidans, and other pathogens from birth (46, 47). Failure to clear these pathogens 
eventually leads to a positive feedback loop of neutrophil recruitment, degranulation, and 
ineffective clearance. This can be observed in the bronchoalveolar lavage fluid (BALF), 
where there is a large percentage of neutrophils recovered from these patients, as well as 
increasing concentrations of the chemokine IL-8, correlating with bacterial infection (48). 
Progressive bronchiectasis as a result of this inflammatory cycle, and mucus plugging from 
the hyper-viscous submucosal gland secretions, significantly hampers lung function, as can 
be observed through FEV1PRED measurements (43, 49). This lung disease is the leading 
cause of morbidity and mortality in CF patient populations (42, 43, 47, 50, 51). 
Often, bacteria in CF airways will undergo genetic changes in order to survive the 
harsh inflammatory environment. Some of the more pathogenic bacterial strategies involve 
the development of mucoid phenotypes in P. aeruginosa species, and the formation of 
biofilm production in P. aeruginosa and many other CF-derived species (52, 53). Antibiotic 
treatment strategies will select for mutants with high intrinsic antibiotic resistance, and as 
such, antibiotic resistance will rapidly spread throughout the patient (54). As expected, 
antibiotic resistance rates for CF patients are high, with 15% of patients colonized with 
multi-drug resistant P. aeruginosa, although rates have been reported as high as 30% of P. 
aeruginosa infected patients; drug-resistant S. aureus is observed in ~25% of patients (54–
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56). As a result, some antibiotics have become completely ineffective for CF patient 
therapy, as it was observed in one study that over 70% of P. aeruginosa isolates were 
resistant to amikacin, gentamicin, and fosfomycin, while over 90% of methicillin-resistant 
S. aureus (MRSA) isolates were resistant to both clindamycin and erythromycin (57). 
Eventually, physicians and patients are burdened with severely limited antibiotic options, 
and the chronic lung infections caused by the multi-drug resistant bacteria result in hypoxia, 
respiratory failure, and death (43). 
While the understanding of CF pathophysiology has been well documented through 
the use of various in vitro cell culture models and in vivo animal models that accurately 
model the human course of disease, the development of multi-drug resistant bacterial lung 
infections remains the most challenging clinical problem to manage. However, the ability 
to isolate and culture multi-drug resistant bacteria allows for multiple permutations of in 
vitro testing, including investigating the bactericidal activity of novel antimicrobial 
agents against these clinically-isolated pathogens. 
1.2.2 Ventilator-associated pneumonia 
Ventilator-associated pneumonia (VAP) is the development of lower respiratory 
tract infection >48 h after the initiation of treatment, and is one of the most common 
hospital-acquired infections (58). Similar to the complex pathology associated with CF and 
the development of CF-lung disease, the development of VAP is equally complex. The 
development of VAP has been attributed to multiple different factors, such as damage 
caused by the insertion of the tube leading to a breached epithelial defense layer, ineffective 
host defense systems, and the patients’ impaired ability to swallow respiratory secretions, 
all resulting in spontaneous airway colonization (59). Consistent with this variable disease 
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etiology, the reported percentages of patients that develop VAP also vary widely, with 
reports anywhere between 5-72% of patients receiving mechanical ventilation (60, 61). The 
mortality rates for VAP patients is equally variable, with reports anywhere between 20-
76%, depending on the study (60, 62). Bacterial species commonly associated with these 
infections include S. aureus, P. aeruginosa, Klebsiella pneumonia, and Acinetobacter 
baumii (63). 
Regardless of incidence rates, the pathology of VAP is similar to community-
acquired pneumonia, with the major complication of an endotracheal tube. To complicate 
the treatment of this pneumonia infection, the endotracheal tube acts as a reservoir for 
bacteria, preventing the ability of the host defense system to completely clear the infection 
(59). In addition, bacteria grown in this environment often form a biofilm, which makes 
treatment of the infection even more difficult, as the biofilm acts as a shield to protect the 
bacteria from host defense systems and antibiotic penetration (64).  
Similar to CF patients, the prolonged bacterial colonization leads to rampant 
pulmonary inflammation, eventually resulting in respiratory failure and death. Although 
BALF collected from these patients is typically used to perform bacterial culture analysis, 
analysis of this fluid presents with high rates of neutrophil influx and cytokine production 
(58, 60, 61, 64, 65). Antibiotics are administered to manage these infections, but prevalence 
of antibiotic resistant bacteria is anywhere between 42-69% (63, 66–69). Left untreated, 
oxygenation becomes severely reduced and patients can develop acute respiratory distress 
syndrome, eventually leading to multi-organ failure and death (60). 
Despite the high incidence of multi-drug resistant infections associated with VAP, 
the overall injury is severely understudied. However, there are multiple animal models 
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useful for investigation, and useful physiologic measurements to investigate, such as 
bacterial clearance, as well as oxygenation and inflammatory responses. These animal 
models allow for a controlled environment in order to investigate VAP infections (70). 
Using these models, it is possible to investigate the therapeutic potential of 
antimicrobial/immunomodulatory agents that directly affect three clinically relevant 
outcomes – oxygenation, bacterial clearance, and inflammation. 
 
1.3 Antimicrobial Resistance and the need for novel therapeutics 
As mentioned previously, the typical treatment for prolonged bacterial infection of 
the airways is the administration of antibiotics. However, improper antibiotic usage, or 
prolonged exposure to antibiotics without effective clearance of the bacteria, such as the 
situation observed in cystic fibrosis patients, can lead to the development of drug-resistance 
(71).  
Increasing rates of multi-drug antibiotic resistance are quickly becoming a concern 
in clinical settings, which limits the therapeutic options available to both patients and 
physicians (6, 72–74). Antimicrobial resistance is one of the largest global threats currently 
being faced, which has been caused by 1) the natural selection of drug-resistant bacterial 
strains due to improper antibiotic use, as well as 2) poor stewardship of conventional 
antibiotics and improper administration (75). In addition to intrinsic resistance strategies 
found within the bacteria naturally, spontaneous mutations and horizontal gene transfer can 
cause rapid dissemination of drug resistance, making the antibiotics ineffective against the 
once-susceptible bacterial strains (52, 76). The increasing incidence of drug-resistant P. 
aeruginosa, MRSA, and a variety of other bacterial species, is threatening treatment 
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regimens of pneumonia patients, as therapeutic strategies become limited by the decreasing 
number of effective antibiotics (4). In case of CF and VAP, the situation is more dire, with 
drug-resistant bacteria being responsible for infection in between 9.2 – 26% and  42 - 69% 
of cases, respectively (63, 66–69, 77). 
The rising prevalence of antimicrobial resistance requires investment into the 
development of new antibiotics. However, with fewer pharmaceutical companies investing 
in the discovery of new therapeutics, there is a reduced number of new therapeutics 
currently in development (75, 78). Consequently, a number of research groups have begun 
to investigate the potential of antimicrobial peptides (AMPs) as potential sources of new 
therapeutics (79–86). 
 
1.4 Antimicrobial peptides 
Antimicrobial peptides are a diverse group of endogenous peptides produced as part 
of the innate immune system. They have been identified in almost every plant and animal 
species investigated. A full list of the 2600+ peptides can be found here 
(http://aps.unmc.edu/AP) (87). These peptides can be subdivided into different groups, 
based on their tertiary structures, amino acid composition, or the ability to form disulphide 
bonds through specific cysteine residues (87).  
The two largest families within the antimicrobial peptide class are cathelicidins and 
defensins. For the purpose of this literature review, we will focus solely on the role of 
cathelicidins, and their potential for the treatment of multi-drug resistant bacterial 
infections. 
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1.4.1 Cathelicidins: mechanisms of action and therapeutic potential 
Cathelicidins are a diverse family of peptides found in multiple species, including 
(but not limited to) humans (88), rats (89), mice (90), and chickens (91). They are grouped 
together based on a common pro-domain, known as a “cathelin” domain (named due to its 
homology to the cathepsin-L-inhibitor), that is roughly 100 amino acids long (92, 93). The 
full-length, unprocessed peptides contain a short signalling domain on the N-terminus, the 
conserved cathelin domain, and the active cathelicidin peptide at the C terminus (94). The 
N-terminal signal domain is responsible for directing the cathelicidin into storage granules, 
at which point it is proteolytically removed (95–98). Once the secretory granules are 
released, or fused with phagosomes, the active C-terminus is cleaved from the cathelin 
portion by elastase (or proteinase 3, specifically for LL-37), releasing the active 
antimicrobial peptide (96–104). Cathelicidins were first identified in leukocytes and 
myeloid cells, but have since been identified in almost all epithelial and immune cells, 
adding evidence for their important role in innate immunity (94, 105–111). Recently, 
cathelicidin expression levels in circulating immune cells was investigated, which showed 
highest levels of cathelicidin expression in neutrophils, followed by monocytes, and then 
lymphocytes (112). Their expression and release can be both constitutive or upon 
stimulation, either through activation by microbial products such as lipopolysaccharide 
(LPS), or through stimulation by inflammatory cytokines, such as IL-1α (110, 113, 114). 
In humans and primates, induction of cathelicidin production is regulated by vitamin D 
receptor activation, not direct NF-κB regulation (115). Instead, toll-like receptor activation 
induces cathelicidin production indirectly, via upregulation of the vitamin D receptor (116). 
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1.4.2 Antibacterial activity 
Initial interest in these peptides was due to their bactericidal properties (117). 
Despite being phylogenically ancient, these peptides have maintained potent antimicrobial 
activity with very few species of bacteria presenting with intrinsic resistance towards them. 
The efficacy of these evolutionarily old peptides is due in part to the multiple mechanisms 
of bactericidal activity (100, 118).  
Upon their release from the secretory granules, the positively charged cathelicidins 
interact with the negatively charged phospholipids found on the bacterial plasma 
membrane, as well as components of the outer membrane, including lipoteichoic acid 
(LTA) or LPS (119). These electrostatic interactions account for the selection of bacterial 
cell membranes over the neutrally charged eukaryotic membranes (79). After the 
interaction with the cell membrane, cathelicidins have been shown to function through two 
methods (Figure 1.1). The first is solely through the cell membrane interactions, where the 
peptides will permeabilize bacterial membranes through either carpet-, barrel stave-, or 
toroidal pore-models, depending on the peptide in question (which varies due to each 
cathelicidin’s structure, shape, and amino acid composition) leading to loss of membrane 
integrity and bacterial death (100, 120–122). While it is possible for bacteria to undergo 
major membrane neutralization to prevent cathelicidin binding, these changes often lead to 
an evolutionary disadvantage once the selective pressure is removed. Additionally, 
bacterial membrane neutralization appears to be limited, and the membrane changes are not 
enough to completely prevent cathelicidin activity (123, 124).  
In the second method, after binding and insertion into the bacterial membrane, the 
peptide will move into the cell and interact with negatively charged molecules within 
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(including DNA and RNA, amoung others) to prevent transcription, translation, and other 
necessary bacterial survival activities (125). These multiple mechanisms of action make 
rapid development of resistance very difficult for bacteria, and explains why these 
phylogenetically ancient peptides still remain effective antimicrobials (124).  
In multiple studies, cathelicidins have repeatedly been shown to effectively kill 
Gram-positive, Gram-negative bacteria (108, 126), mycobacteria (104), as well as fungi 
(127), and to neutralize membrane-enveloped viruses (128, 129), all of which are the 
sources of clinically relevant infections in the airways. However, while their bactericidal 
role has been well established in vitro, there are concerns about the activity of these peptides 
within physiologically relevant settings. Travis et al. showed that, while all cathelicidins 
investigated had potent bactericidal activity in the absence of salt, only two peptides 
(SMAP-29 from sheep and CAP-18 from rabbits) showed similar bactericidal activity at 
“high” salt concentrations (100mM NaCl) (130), which is still lower than physiologically 
relevant conditions found within the lung (131). Other peptides, however, have been shown 
to have salt-insensitive activity, such as CATH-2 (101, 132). However, various 
modifications can affect bactericidal activity in these high salt conditions, as Veldhuizen et 
al. demonstrated that shortening of cathelicidins, particularly through truncations to the C-
terminal of the peptide, tends to lead to increased salt sensitivity with respect to 
antimicrobial activity. They postulated that α-helix stability was one of the factors behind 
the disparity in activity (133).  
Regardless of the controversy surrounding their direct bactericidal role in vivo, 
cathelicidins have been repeatedly shown to have direct anti-infective functions in 
clinically relevant models of infection. They were first identified as key members of 
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immunity in mouse models of Group A S. pyogenes skin infection, where loss of mCRAMP 
expression via knockout led to reduced clearance of the bacteria and an increase in the 
necrotic tissue area at the site of infection (134). This was one of the earliest studies to 
provide direct evidence of cathelicidin function in vivo, which initiated the investigation of 
these peptides in other disease models, including respiratory infections. 
In CF, despite the failed bacterial clearance by the immune system, there are 
significantly elevated levels of LL-37 within the sputum, which correlates with disease 
severity (135). However, sputum samples that were treated with lipopolysaccharide-
binding protein (LBP) and DNase in vitro were able to reduce bacterial load, presumably 
by releasing the AMPs within the sputum from LPS and DNA/F-actin that may have been 
binding to and masking the peptide’s direct bactericidal functions (136, 137). Loss of 
endogenous cathelicidin expression in vivo has been shown to significantly reduce bacterial 
clearance in infection models using K. pneumoniae and P. aeruginosa, again demonstrating 
the important role of cathelicidins in the innate immune response towards bacterial 
infections (138). 
Despite the vast amount of research investigating the potential of cathelicidin 
peptides as exogenous therapies, administration of exogenous cathelicidins and 
cathelicidin-derivatives to directly treat bacterial lung infections in vivo have shown much 
more modest results to date. A recent study by Mardirossian et al showed that, despite 
efficacy in vitro and peptide tolerability in naïve animals, intratracheal instillation of 
BMAP-27 and its peptide derivatives was unable to significantly reduce P. aeruginosa 
bacterial load 24 hours after treatment (139). Using a similar model, Beaumont et al showed 
that intratracheal administration of LL-37 after P. aeruginosa infection aids in the bacterial 
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clearance, but via augmentation of the endogenous host defense system, not through direct 
bactericidal activity (140). 
Taken together, these studies provide evidence of the disparity in cathelicidin 
activity between individual peptides with respect to direct bactericidal activity. The lack of 
translational activity between in vitro studies and actual effects observed after in vivo 
administration highlight the need for thorough investigation of various cathelicidins in 
order to identify an optimal peptide which maintains salt-insensitive, in vivo bactericidal 
activity, in order for further development of a clinical therapeutic agent.  
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Figure 1.1. a) A cartoon ribbon model of two α-helix structured cathelicidin peptides; 
CATH-2 (blue), and LL-37 (red). b) Cathelicidins have been found to be endogenously 
released by both macrophages (light blue), neutrophils (purple), and epithelial cells (not 
shown) after induction of inflammatory signalling, at which point the peptide is now free 
to interact directly with the bacterial membrane to begin bactericidal activities. The three 
proposed mechanisms of bactericidal activity via pore formation are c) barrel-stave model, 
where the neutrally-charged portion of the cathelicidin interacts with the lipid tail groups 
of the bacterial cell membrane, eventually forming a pore; d) the toroidal pore model, in 
which the positively-charged portions of the peptide interact with the negatively-charged 
phospholipid head groups by inserting into the bacterial membrane, forcing the membrane 
to fold inwards as well; e) carpet model, in which the peptides orient in parallel to the 
bacterial membrane, and upon reaching a “critical” concentration, form micelle-like 
structures and lyse the cell membrane. f) Mechanisms of intracellular activity, which 
include inhibition of DNA, RNA, and protein synthesis. 
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1.4.3 Cathelicidin immunomodulatory activity 
As a result of the unclear nature of cathelicidins’ bactericidal activity in vivo, some 
research groups have begun testing cathelicidin immunomodulatory activity (83, 141–143). 
It has been well documented, both in vitro and in vivo, that cathelicidins are able to 
modulate inflammatory signalling, by either eliciting a pro-inflammatory or anti-
inflammatory signal, which appears to be dependent upon microbial stimulation and 
microbial by-products initiating the signal (140, 144, 145). 
The presence of the human cathelicidin LL-37 has been shown to skew 
differentiating monocytes towards M1 (pro-inflammatory) macrophages (146). However, 
LL-37 has been shown to be able to reduce pro-inflammatory cytokine production from 
these M1 macrophages if co-administered with LPS or LTA at physiologically relevant 
levels, without affecting macrophage phagocytic activities (82). There is evidence that LL-
37 appears to inhibit cytokine expression of stimuli activating the toll-like receptors TLR 
2 and TLR 4 (LTA and LPS, respectively) (144). However, this anti-inflammatory activity 
appears to be very specific, as cytokine production after stimulation by of TLR2/1 via the 
synthetic lipopeptide PAM3, or TLR2/6 via ZymA is not affected by administration of LL-
37 (82, 146).  
Asides from LL-37, other cathelicidins have been shown to have similar activity 
across several distinct species. Murine CRAMP has been shown to act similarly to LL-37, 
inducing macrophage polarization and reducing cytokine production upon microbial 
stimulation by LPS, LTA, as well as bacterial flagellin (a TLR 5 agonist) (147). Chicken 
cathelicidins CATH-1, -2, and -3 have been shown to similarly block LPS-induced cytokine 
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production from mouse macrophage cell lines, which importantly indicates cross-species 
activity (101, 132, 148). 
However, the anti-inflammatory properties of cathelicidins are not as straight-
forward as initially suspected. Both LL-37 and CATH-2 have been shown to be involved 
in the association of DNA complexes that activate TLR 9 and increase inflammatory 
signalling (149, 150). Similarly, mCRAMP-knockout (CAMP-/-) mice showed a reduced 
ability to respond after CpG DNA injection through a reduction in inflammatory cytokine 
production (TNF-α, IL-6), while it was shown at the same time that mCRAMP is 
responsible for complexing with CpG DNA and TLR 9 in the endolysosome of murine 
macrophages (151). 
 Adding to their immunomodulatory properties, many cathelicidins have also been 
documented to act as chemoattractant agents. LL-37 has been shown to induce chemotaxis 
in monocytes, neutrophils (152), eosinophils (153), and T-cells (154). Similar neutrophil 
chemotactic activities have been found for additional peptides, such as mCRAMP, PR-39 
(155), and chicken CATH-1 (156), while mononuclear cell recruitment appears to be less 
universal. The chemotactic functions of these peptides appears to be regulated through the 
formyl peptide receptor 2/formyl peptide receptor-like 1 (FPR2/FPRL1) (152). Similar 
receptor interactions have been identified for other species, such as mCRAMP and the 
murine homologue of FPR2 (157). For mast cell specific mobilization and activation, LL-
37 has been able to act through the MrgX2 receptor specific to mast cells (158). There is 
also some evidence of LL-37 acting as a direct ligand for the CXCR2 chemokine receptor 
found on neutrophils, where interaction induces calcium influx in a dose-dependent manner 
(159). 
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Independent of their direct chemotactic activity, cathelicidins are also able to 
upregulate the production of chemokines from other cell types. Macrophages stimulated 
with LL-37 produced significantly higher levels of MCP-1, a key chemokine for the 
recruitment of monocytes, natural-killer cells, and T-cells, however LL-37 incubation with 
LPS inhibited the release of MCP-1 from airway epithelia. Additionally, stimulation with 
LL-37 alone produced IL-8, a neutrophil chemokine, in a dose dependent manner (160). 
This IL-8 production appears to be through the interaction of these peptides with both the 
P2X7 receptor and epidermal growth factor receptor, and has been shown to be produced 
from epithelial cells, fibroblasts, and macrophages (161–163). LL-37 binding with GAPDH 
from monocytes also induces the production of CXCL1, another neutrophil chemokine 
(145). 
Based on the studies of immunomodulatory activities described above, cathelicidins 
have become attractive therapeutic targets as immune system adjuvants. Summation of the 
data presented above suggests that cathelicidins have the ability to maintain a complex 
inflammatory balance within an infection environment. This capability to balance the 
immune system, ensuring a sufficient inflammatory response to eliminate invading 
pathogens while preventing excessive host responses, suggests that cathelicidins are 
extremely promising as therapeutics for many chronic lung diseases, and especially CF 
lung disease where excessive pro-inflammatory activation often leads to collateral tissue 
damage and remodelling. The use of a cathelicidin peptide that possesses antibacterial 
activity in vivo, while being able to modulate inflammatory responses, would be an ideal 
therapeutic for this type of disease. 
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1.4.4 Chicken cathelicidin CATH-2 
CATH-2 is one of four cathelicidins found in chickens (91). Produced almost 
exclusively by heterophils (chicken homologue of human neutrophils), the active CATH-2 
peptide is cleaved from its pro-piece by serine proteases and released upon immune system 
stimulation, such as LPS activation (164). Once released, the peptide can exert its potent 
broad-spectrum microbicidal activity (127, 132). CATH-2 shows antimicrobial activity 
against a wide variety of both chicken and human pathogens, generated minimum 
inhibitory concentration (MIC) values between 0.6-5.3 µM. Unlike other cathelicidin 
peptides, this antimicrobial activity appears to be unaffected by increasing salt 
concentrations (101, 132, 165). CATH-2 appears to kill through multiple mechanisms of 
action, depending on peptide concentration, including direct membrane permeabilization, 
as well as interacting with intracellular components, although the exact target is unknown 
(166). 
In addition to this salt-insensitive broad-spectrum activity, CATH-2 has also been 
shown to have strong immunomodulatory activity. It has been shown to directly bind to 
multiple immunostimulatory products, such as LPS (132, 166, 167). Interactions of CATH-
2 with LPS, as well as the gram-positive endotoxin LTA, are able to significantly reduce 
TNF-α production from macrophages in vitro, while interactions with CpG DNA increases 
TNF-α production, consistent with observations from other cathelicidin peptides (151, 
167).  
In vitro, CATH-2 has demonstrated the unique ability to kill a broad-spectrum of 
human pathogens, maintains bactericidal activity within physiologically relevant salt 
concentrations, and is able to modulate inflammatory responses in vitro across multiple 
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different stimulatory molecules, in both chickens, as well as mouse cell lines. Based on 
both its bactericidal and immunomodulatory effects, CATH-2 is a highly promising 
cathelicidin of interest for further investigation. However, the use of CATH-2 in in vivo 
models, and its bactericidal activity against multi-drug resistant human pathogens, is yet 
unknown. 
 
1.5 Cathelicidins in clinical trials  
Due to their multiple mechanisms of bactericidal activity, cathelicidins are ideal 
peptides for next generation antibiotics due to their low propensity for the development of 
bacterial resistance. Despite the bacterial development of protease secretion and 
membrane/exotoxin post-translational modifications as possible resistance mechanisms, 
the fact that these peptides retain broad-spectrum activity against a variety of human 
pathogens reinforces their clinical potential in future therapies (124). 
According to ClinicalTrials.gov, there are currently approximately 80 trials 
involving cathelicidins, as well as other antimicrobial peptides, either through direct 
administration of exogenous antimicrobial peptides, through treatments aimed to increase 
endogenous cathelicidin pool sizes within patients (through the administration of butyrate, 
vitamin D, or their alternative forms), or through treatments aimed at the inhibition of 
cathelicidin production for diseases of peptide over expression. In addition, there is a large 
field of research involving pre-clinical studies investigating multiple cathelicidin peptides 
in many infection and disease states (141). 
However, despite the therapeutic promise of cathelicidin peptides, very few have 
been developed through all stages of clinical trials. Obstacles to development often involve 
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either toxicity towards eukaryotic cells, which can be observed at high doses (101), or the 
poor stability of cathelicidin peptides to endogenous proteases found in the gastrointestinal 
tract, serum, and even bronchoalveolar lavage fluid (83, 139). Therefore, optimal 
cathelicidin therapy for pulmonary infections would require a) a peptide that is functional 
in the pulmonary, high salt, environment, b) a method to protect the peptide from 
degradation, limited toxicity, and c) a method to deliver it directly to the injured location.  
 
1.6 Delivery of therapeutics to the airways 
During treatment of lower respiratory tract infections, adequate 
antibiotic/antimicrobial site concentrations are imperative for the clearance of infection. 
This is made difficult by the unique branching structure of the lung (168). Despite this, the 
delivery of antibiotics directly to the site of infection within the lung, which is currently 
limited to aerosolized administration, has numerous benefits over current systemic 
administration routes, including increased local concentrations of antibiotics, and enhanced 
microbial clearance. Furthermore, there is a reduced risk of systemic toxicity which is 
common in numerous conventional antibiotics (29, 169–171). However, aerosolized 
administration of antibiotics is typically found to accumulate in the central airways, with 
large volumes of antibiotics required to reach adequate concentrations at the distal sites of 
infection (30, 172, 173). Therefore, to optimize delivery of therapeutics to the lungs, other 
drug delivery vehicles must be identified. 
1.6.1 Exogenous pulmonary surfactant as a vehicle for therapeutic delivery 
In order to overcome these delivery issues, many groups have investigated the 
potential of pulmonary surfactant as a delivery vehicle (29, 169, 170, 174–177). Pulmonary 
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surfactant is a lipoprotein mixture, endogenously produced by type II alveolar cells within 
the lung, composed of approximately 80-85% phospholipids, 5-10% neutral lipids, and 5-
10% surfactant specific proteins (9, 13). Exogenous clinical surfactants, derived from 
animals including bovine and porcine sources, have been used over the past 35 years as a 
treatment for neonatal respiratory distress syndrome, which is characterized in premature 
infants as a lack of sufficient endogenous surfactant (19, 178, 179). Surfactant acts by 
adsorbing and spreading at the air-liquid interface within the alveoli and acts to reduce 
surface tension, thereby improving lung compliance and preventing alveolar collapse upon 
exhalation (14). 
The spreading capabilities of surfactant has been investigated as a potential 
mechanism of distributing therapeutics to distal airways (29). The benefits of surfactant 
spreading were first demonstrated by Kharasch et al., who showed that surfactant 
administration was superior to aqueous solution administration with regards to lung tissue 
distribution (30). They demonstrated that surfactant was able to disperse more uniformly 
throughout the lungs, in comparison to saline solution, which tended to localize to the 
central lung regions (30). Surfactant distribution rates are also far superior to current 
practices involving aerosolized administration, which only achieves ~10% deposition in 
small airways (180, 181). 
Based on the promise of these initial distribution studies, several groups began 
investigating the potential of utilizing surfactant as a respiratory vehicle, with the purpose 
of increasing concentrations of therapeutics at the infection site and reducing toxicity risks 
of systemically administered antibiotics (29, 30, 170, 176). Van’t Veen et al. were able to 
show that the combination of surfactant with the antibiotic tobramycin was able to 
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significantly improve survival in mice infected with K. pneumoniae compared to animals 
receiving surfactant alone, or tobramycin alone (176). The same group was then able to 
show that the in vivo administration of a surfactant preparation with cyclosporine A 
suspended in ethanol had no impact on surfactant function (177), and were able to reduce 
inflammation and acid sphingomyelinase activity after “fortification” of surfactant with a 
NF-κB inhibitor (182). 
As mentioned previously, pulmonary surfactant has been used as a clinical therapy 
from 1980 for the treatment of neonatal respiratory distress syndrome (25). While the use 
of surfactant for the treatment of adult respiratory distress syndrome failed to show 
significant clinical improvement, it has repeatedly been demonstrated to be a safe 
therapeutic (183). However, more recent studies have begun investigating the potential of 
surfactant as a mucokinetic agent, which would act to improve clearance of mucus plugging 
(184). Studies by Al-Saiedy et al. demonstrated that the addition of the exogenous 
surfactant BLES to an in vitro mucus plug system was able to improve mucus “velocity” 
over the course of ventilation (185).  
Along with its potential as a respiratory vehicle, the multifunctionality of a 
combined surfactant/antimicrobial peptide compound to distribute therapeutics throughout 
the airways, reduce mucus plugging, and eliminate multi-drug resistant bacteria would be 
of major therapeutic benefit as a treatment for many different respiratory diseases, 
including cystic fibrosis and ventilator-associated pneumonia. However, as demonstrated 
by van’t Veen et al., this combination must be able to maintain the innate functions of each 
of its parts, as some antibiotics have demonstrated a loss of activity after instillation with 
surfactant, and surfactant inactivation would compromise lung function (175). 
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1.7 Summary, objectives, and hypothesis 
 Over the course of respiration, the lung is constantly bombarded with pathogenic 
bacteria. In some cases, these bacteria are able to circumvent the natural host defense 
systems and develop into an airway infection. Left untreated, these infections can lead to 
severe tissue damage in the lungs, resulting in inefficient gas exchange, poor oxygenation, 
respiratory failure, and eventually death. Normally, treatment of these infections involves 
a simple course of antibiotics, resulting in clearance of the pathogen. However, ineffective 
antibiotic stewardship combined with a lack of pharmaceutical investment has cumulated 
into a global healthcare “perfect storm” with the increasing emergence of antibiotic 
resistant bacteria. There is a dire need for the development of novel therapeutics for 
the treatment of antibiotic resistant bacterial infections. 
 To develop these new therapeutics, we have investigated the potential of 
cathelicidin peptides. Their direct antimicrobial activity, coupled with their 
immunomodulatory functions, are theoretically ideal for the treatment of infection, as they 
present the ability to directly kill colonized bacteria while downregulating the inflammatory 
response associated with bacterial death. In addition to cathelicidins, we have investigated 
an exogenous pulmonary surfactant, BLES, as a vehicle for these cathelicidin peptides, in 
order to improve therapeutic administration into the peripheral airways of the lung.  
 However, interaction between cathelicidin peptides and exogenous pulmonary 
surfactant is currently unknown. In Chapter 2, we investigated the proof-of-principle of 
a cathelicidin/surfactant compound, and select an optimal cathelicidin for therapeutic 
use. This investigation was performed by assessing the biophysical and antimicrobial 
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activities of multiple cathelicidin peptides in combination with exogenous surfactant in 
order to select an ideal peptide/surfactant combination for future therapeutic study. Once 
identified, we tested the safety of this therapeutic after intratracheal administration in naïve 
animals.  
 After identifying the optimal cathelicidin/surfactant combination, and performing 
safety studies, Chapter 3 investigated the immunomodulatory activity of the selected 
cathelicidin, CATH-2, using administration of killed P. aeruginosa. Bacteria were 
killed via three separate mechanisms, and intratracheally instilled into mouse lungs in order 
to study the inflammatory response elicited. The ability of CATH-2 to kill bacteria in an 
immunogenically “silent” manner, as well as the ability of CATH-2 to down-regulate the 
inflammatory response of other killed-bacteria were investigated. 
 Following the investigation of CATH-2’s immunomodulatory activity, Chapter 4 
focused on the bactericidal and immunomodulatory properties of BLES+CATH-2 
against multi-drug resistant clinical isolates obtained from CF patients. Similar to 
previous methodology, we investigated the in vitro bactericidal activity of BLES+CATH-
2, and investigated the immunomodulatory activity of BLES+CATH-2 upon instillation in 
vivo with heat-killed bacteria. 
 Finally, in Chapter 5 we investigated the bactericidal and immunomodulatory 
activity of BLES+CATH-2 in two distinct models of pneumonia. To test this, two 
models - a mouse model of bacterial pneumonia, and a rat model of ventilator-associated 
pneumonia - were used to assess the bactericidal activity of BLES+CATH-2 treatment in 
vivo in clinically relevant models of respiratory infections. 
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The overall objective of this thesis was to develop an antibiotic-alternative, novel 
therapeutic for the treatment of multi-drug resistant respiratory infections. The overall 
hypothesis is that the administration of a cathelicidin/surfactant compound will improve 
clinically relevant outcomes in the treatment of bacterial pneumonia.  
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antimicrobial peptide for the treatment of bacterial 
pneumonia: antimicrobial and biophysical properties 
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2.1 Introduction 
The emergence of highly resistant strains of bacteria currently represents a 
significant public health issue for patients due to the pervasive use of antibiotics on a global 
scale. Patients with acute or chronic pulmonary infections where antibiotic use is 
widespread, such as in case with cystic fibrosis and ventilator-associated pneumonia, 
antimicrobial resistance is particularly problematic and is a strong predictor of poor 
outcomes (1). Furthermore, the distinct structure of the lung, combined with the potential 
of inaccessible areas due to collapse and edema arising from infections, significantly 
impairs effective antimicrobial drug delivery in this organ. New, innovative therapeutic 
approaches to combat lung infections are desperately needed. 
Antimicrobial peptides (AMPs) form part of the innate immune system and are 
evolutionarily conserved across a wide variety of organisms including humans (2). One 
class of antimicrobial peptides, cathelicidins, possess antimicrobial function through a 
variety of mechanisms including direct interaction with bacterial cell membranes and 
interference of intracellular bacterial targets (2). The net positive charge of these peptides 
ensures they are more likely to interact with the negative cell walls of bacteria than the 
neutral cellular membranes of eukaryotic cells. Importantly, it has been demonstrated that 
they remain functional against microbes with antibiotic resistance, and considering their 
mechanism of action, it is less likely that resistance will develop due to the changes in 
membrane structure that would be required for effective resistance (2). It has been shown 
in vitro that AMPs can induce transient resistance, but there is no evidence that this occurs 
in vivo (3). Based on these properties, antimicrobial peptides have received a lot of attention 
as alternatives to antibiotics, particularly for topical therapies (4). Utilization for pulmonary 
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infections has been investigated but is complicated by delivery issues and to date has not 
been successful in clinical trials (5–7). 
To address the pulmonary delivery issue, exogenous surfactant has been proposed 
as carrier for a variety of biological agents (8). Exogenous surfactant is derived from 
endogenous pulmonary surfactant, a lipoprotein complex naturally produced by type II 
alveolar cells, that is made up of approximately 80-85% phospholipids, 5-10% neutral 
lipids (including cholesterol), and 10% proteins (9). The main function of surfactant is to 
reduce surface tension at the air-liquid interface of the alveoli. To accomplish this goal, 
surfactant adsorbs and spreads rapidly to form a surface film consisting or lipid-condensed 
and lipid-expanded regions at the air-liquid interface which upon lateral compression forms 
a stable multilayer structure capable of reducing surface tension values to near 0 mN/m (10, 
11). Through its ability to spread throughout the lung and open up collapsed lung areas, 
exogenous surfactant therapy has been shown to reduce mortality of premature infant 
afflicted with neonatal respiratory distress syndrome (12). 
The general characteristics of surfactant and positive findings of exogenous 
surfactant therapy led to a number of laboratory studies to investigate the possibility of 
exogenous surfactant as a pulmonary delivery vehicle for other drugs (13–17). The 
rationale for this approach is that the spreading properties of surfactant would improve 
therapeutic distribution throughout the lung, while opening of collapsed lung regions to 
improve drug availability directly at the site of an infection (8). Imperative for this approach 
is that the drug of choice does not impact surfactant's ability to spread throughout the lung 
and reduce surface tension, and, vice versa, that surfactant does not interfere with the 
therapeutic efficacy of the drug.  
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Based on this information our objective was to evaluate the spreading, biophysical 
capabilities, and bactericidal function of four cathelicidin peptides, CATH-1, CATH-2, 
mCRAMP, and LL-37, combined with a clinical exogenous surfactant, bovine lipid-extract 
surfactant (BLES). Maintenance of respective surfactant and cathelicidin functions when 
the two compounds are combined would provide a first proof-of-principle toward the 
hypothesis that a combination treatment of cathelicidins with an exogenous surfactant 
vehicle would be effective in treating antibiotic resistant lung infections. 
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2.2 Materials and Methods  
Surfactant/Peptide Compounds 
 BLES (BLES Biochemicals, London, ON, Canada) is a commercially available 
clinical preparation, stored in 100 mM sodium chloride and 1.5 mM calcium chloride with 
a phospholipid concentration of 27 mg/ml. BLES contains natural phospholipids found in 
bovine surfactant, along with surfactant-specific proteins SP-B and SP-C and a small 
percentage of cholesterol.   
Antimicrobial peptides were synthesized using Fmoc solid-phase synthesis as 
described previously (18). All peptides were purified to a minimum purity of 95% by 
reverse phase high-performance liquid chromatography prior to biological testing. The 
sequences of the peptides used in this study are shown in Table 2.1. Four AMPs were 
tested in this experiment: chicken cathelicidin-1 and 2 (CATH-1, CATH-2), mouse 
cathelicidin CRAMP, and human cathelicidin LL-37. All peptides were suspended in 
non-buffered sterile saline. BLES and peptide were mixed to concentrations of 10 mg/ml 
BLES, and 10/40/100/200 µM for the peptides. 
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Peptide Amino Acid Sequence Net 
Charge 
CATH-1 RVKRVWPLVIRTVIAGYNLYRAIKKK +8 
CATH-2 RFGRFLRKIRRFRPKVTITIQGSARF +9 
mCRAMP GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ +6 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES +6 
 
Table 2.1 Amino acid sequence and charge of cathelicidins investigated. 
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Spreading 
 Adsorption of BLES and the various peptides were measured using the Wilhelmy 
probe and FilmWare 2.51 software of the Langmuir balance. A petri dish with a diameter 
of 100 mm, and surface area of 78.54 cm2 was used. It was filled with 25 ml of 10% sucrose, 
with a 15 ml layer of ddH2O layered on top. The probe of the Langmuir balance was placed 
on the surface of the ddH2O sub-phase, and 50 µl of each peptide-surfactant sample was 
pipetted into the water phase. The surface tension was recorded over the subsequent 600 
seconds. 
 
Minimal surface tension over multiple compression-expansion cycles 
 To investigate the minimum achievable surface tension over ten compression-
expansion cycles, a constrained sessile drop surfactometer (CDS) (BioSurface Instruments, 
HI) was used (19–21). A ten microliter drop of sample was placed upon the drop pedestal, 
and using an external stepper motor, the drop was cyclically compressed-expanded for 10 
cycles at a rate of 5 seconds/cycle, and a compression ratio of approximately 27%. Images 
of the droplet were recorded at a rate of one image per second, and were analyzed. The 
image with the lowest surface tension throughout each cycle was determined to be the 
minimum surface tension (MST) for that cycle. Minimum surface tensions for all 10 cycles 
were measured. 
 
AFM imaging of surface films  
In order to examine the effect of peptides on the surfactant surface films, Langmuir-
Blodgett films were prepared using a Kibron™ Trough SE (Helsinki, Finland). Briefly, 
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films were spread by depositing droplets of surfactant samples uniformly throughout the 
air–water interface. Deposits were taken at surface pressure of 30 mN/m on freshly-cleaved 
mica. Topographical atomic force microscope (AFM) images were obtained using a 
Nanoscope III scanning force multimode microscope (Digital Instruments, Santa Barbara, 
CA). Samples were scanned with a J-type scanner using contact mode in air. A silicon 
nitride cantilever with a spring constant of 0.12 N/m was used. Image analysis was 
performed using the Nanoscope III software (version 5.12r3). All AFM images were 
subjected to quantitative analysis using ImageJ Software (National Institute of Health) to 
determine the surface area of condensed domains. At least 9 AFM images were used for 
each sample and the results are shown as averages and standard error. 
 
Antimicrobial assays 
 An overnight culture of either Methicillin-resistant Staphylococcus aureus WKZ-2, 
or Pseudomonas aeruginosa VW178 (isolated from a cystic fibrosis patient) were diluted 
1/1000 in tryptic soy broth (TSB) and left to incubate for three hours at 37°C in order to 
reach exponential growth phase. The optical density was measured, and bacteria were 
further diluted in PBS to reach an initial concentration of approximately 2x106 CFU/ml. 
From there, 25 µl of peptides at various concentrations, with or without BLES, were added 
to polypropylene coated round-bottom 96 well plates, along with 25 µl of bacteria, and 
incubated at 37°C for three hours with no shaking. Subsequently, 200 µl of minimal media 
was added, and the colonies were serially diluted 10-1000-fold. After the serial dilution, 
100 µl of each dilution were plated on tryptic soy agar (TSA) plates and left to incubate 
overnight at 37°C. Following overnight incubation, the colonies on the plates were counted. 
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Minimum bactericidal concentrations (MBC) were defined for these experiments as the 
concentration of surfactant/peptide compound at which less than 10 colonies were counted 
at the highest dilution, corresponding to less than 100 CFU/ml. 
 
In vivo analysis of safety and tolerability of BLES+CATH-2 treatment 
 Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 22-30 g, 
were used for this experiment. All animal procedures were approved by the Animal Use 
Subcommittee at the University of Western Ontario, and followed the approved guidelines 
described by the Canadian Council of Animal Care. Mice were anesthetized by 
intraperitoneal injection of a ketamine (100 - 125 mg/kg body weight) and 
dexmedetomidine (0.5 mg/kg BW) mixture, and then intubated using a 20 G catheter, with 
the aid of a fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc., 
Houston, Texas, USA). Once intubated, the mice were instilled with 50 µl of one of five 
treatments: a) air bolus, b) sterile saline, c) BLES (10 mg phospholipid/ml), d) CATH-2 
(100 µM, suspended in sterile saline), or e) BLES+CATH-2 (10 mg phospholipid/ml, 100 
µM peptide).  Mice were extubated following successful instillation and were subsequently 
injected with the reversal agent for dexmedetomidine, Antisedan, and allowed to breathe 
spontaneously for the following four hours. After four hours, the mice were euthanized by 
intraperitoneal (IP) injection of sodium pentobarbital (110 mg/kgBW) and dissection of the 
descending aorta. The animals were placed on a FlexiVent© in order to measure 
physiologic parameters, such as lung capacity, compliance, and airway resistance. 
Following these measurements, whole lung lavage was collected by 3 x 1 ml aliquots of 
sterile saline. The whole lung lavage was immediately centrifuged at 150 x g at 4°C, and 
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the pellet was collected for cell analysis, while the supernatant was used to measure protein 
and IL-6 content. Differential cell analysis of the cells obtained in the lavage was done as 
previously described (22). Protein content within the lavage fluid was measured using a 
Micro BCA protein assay kit (Pierce, Rockford, Ill., USA), according to manufacturer’s 
instructions. IL-6 levels were measured using an enzyme-linked immunosorbent assay 
(ELISA) kit (BD Biosciences, San Diego, Calif., USA), according to manufacturer’s 
instructions. 
 
Statistical Analysis 
 The effect of various cathelicidin peptides on BLES’ surface tension reducing 
capabilities, and adsorptive properties, were calculated by one-way measure analysis of 
variance (ANOVA) followed by a Dunnett post-hoc test using BLES as the control group. 
Analysis of in vivo assays were performed by one-way ANOVA followed by Tukey post-
hoc test. Means are reported ± SEM and values were considered significantly different at a 
probability value < 0.05.  
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2.3 Results 
Surface Tension after 600 seconds 
 Initial assessment involved an analysis of the ability of the surfactant plus peptides 
to form a surface film on a clean air-water interface. This data reflects the “spreadability” 
of the surfactant which, extrapolating to a clinical scenario, is an important indicator of the 
ability of this material to distribute throughout the lung and reach the distal airways and 
alveoli. Each sample was allowed to form a film for 600 seconds and surface tension 
reached was recorded. As shown in Figure 2.1, there were no significant differences in the 
end surface tensions between any of the surfactant/cathelicidin mixtures at 10 µM 
concentrations and BLES (control). However, at a cathelicidin concentration of 40 µM, a 
significant decrease in the surface tension at the end of 600 seconds of spreading was 
observed for BLES+CATH-1 (p<0.01) and BLES+CATH-2 (p<0.05) mixtures compared 
to BLES (control) indicating improved spreading characteristics. All four 
surfactant/cathelicidin mixtures tested resulted in significantly lower surface tension at the 
end of 600 seconds spreading at 100 µM concentrations compared to BLES controls. 
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Figure 2.1 
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Figure 2.1. Adsorption assay of exogenous surfactant BLES in mixture with cathelicidin 
peptides. a) CATH-1, b) CATH-2, c) mCRAMP, and d) LL-37 at concentrations of 0, 10, 
40, and 100 µM. Values are mean surface tension ± SEM after 600s. (n=3) *p<0.05 vs. 
BLES (Control), **p<0.01 vs. BLES (Control). 
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Minimum surface tension over multiple compression cycles 
 In order to examine the surface tension reducing function of the peptide/surfactant 
mixtures, the samples underwent ten cyclic compressions at a rate of five seconds/cycle via 
the CDS, as a physiologically relevant model of multiple expansion-contraction cycles 
during respiration. Minimum achievable surface tension (MST) values were recorded for 
ten cycles, as a marker of surfactant activity which, in the in vivo situation, would reflect 
the ability of this material to stabilize the alveoli and allow for ease of inflation. BLES 
alone was able to reach MST values of ~2.5 mN/m consistently over all ten cycles. It was 
observed that all concentrations of BLES+CATH-2 had a robust surface tension reducing 
activity, consistently reaching MST values below 4 mN/m. BLES+CATH-2 only showed 
significantly higher MST values at cycles 8, 9, and 10 at a concentration of 10 µM 
compared to BLES (control). BLES+CATH-1 mixtures at 40 and 100 µM concentrations 
showed significantly higher MST values compared to BLES (control) at cycles two through 
ten (Figure 2.2a), increasing slightly from 4 mN/m to MST of roughly 5 mN/m at the end 
of the ten compressions. BLES+mCRAMP mixtures had consistently higher MSTs of 
approximately 4.5 mN/m over all cycles at 40 and 100 µM compared to BLES alone (Figure 
2.2c). BLES+LL-37 mixtures had significantly increased MSTs between 4.5-5.5 mN/m 
over all cycles versus BLES (control), but only significantly different at concentrations of 
10 and 40 µM (Figure 2.2d). Minimum surface tensions of BLES+LL-37 mixtures at 100 
µM were not statistically different from the BLES (control). Mixtures of BLES+CATH-2 
were the only surfactant/cathelicidin mixture to show no significant difference versus 
BLES (control) at 40 and 100 µM concentrations. 
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Figure 2.2 
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Figure 2.2. Measurement of minimum surface tension during cyclic compressions of 
exogenous surfactant BLES in mixture with cathelicidin peptides. a) CATH-1, b) CATH-
2, c) mCRAMP, and d) LL-37 at concentrations of 0 (open circle), 10 (triangle), 40 
(diamond), and 100 µM (circle). Values are mean minimal achievable surface tension ± 
SEM. (n=3-5) α = 10 µM <0.05 vs. BLES (Control), β = 40 µM < 0.05 vs. BLES (Control), 
δ = 100 µM <0.05 vs. BLES (Control). 
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Atomic force microscopy images  
 To assess the influence of peptides on surfactant film structure, AFM images were 
analyzed focusing specifically on the formation of liquid condensed domains, as these 
domains have been suggested to be important in surfactant function (11). Characteristic 
AFM topographic images of BLES films in the absence and presence of 100 µM peptides 
(CATH-2, CATH-1, LL-37 and mCRAMP) are shown in Figure 2.3. The brightness in 
these images is proportional to the height.  Phase separation, as indicated by the presence 
of lighter, condensed domains, is evident in all samples at surface pressure of 30 mN/m 
(Figure 2.3 a-e). Quantitative analysis of these images shows that addition of CATH-1 and 
CATH-2 to BLES leads to a change in its lateral organization.  More specifically, addition 
of CATH-1 and CATH-2 to BLES leads to an increase in the number of condensed domains 
and a decrease in the average surface area of the individual domains (Figure 2.4). Addition 
of LL-37 and mCRAMP to BLES has no significant effect on average surface area of 
condensed domains at surface pressure 30 mN/m (Figure 2.4). 
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Figure 2.3 
 
Figure 2.3. Characteristic AFM topographic images showing the effect of peptide addition 
on the lateral organization of BLES monolayers. The scan area is 20 x 20 µm2. All films 
were deposited at a surface pressure of 30 mN/m. (a) BLES; (b) BLES + 100 µM CATH-
1; (c) BLES + 100 µM CATH-2; (d) BLES + 100 µM mCRAMP and (e) BLES + 100 µM 
LL-37. 
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Figure 2.4 
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Figure 2.4.  Quantiﬁcation results showing the effect of peptide addition (CATH-1, CATH-
2, mCRAMP, and LL-37) on the size (i.e. surface area) of the condensed domains in BLES 
monolayers at surface pressure 30 mN/m. These results were obtained from four unique 
AFM topographic images of different samples. (n=2-24) 
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Antimicrobial assays 
 In order to determine the bactericidal properties of the surfactant/cathelicidin 
mixtures, bactericidal assays of each peptide were performed in both the presence and 
absence of BLES. CATH-1, CATH-2, and LL-37 in PBS were found to have MBC values 
of 5 µM, reducing CFU/ml values of MRSA by more than four log units (Figure 2.5a,b,d), 
while mCRAMP reduced levels by three log units at 40 µM concentrations (Figure 2.5c). 
In the presence of BLES (Figure 2.5), CATH-2 had a MBC of 200 µM, but had considerable 
antimicrobial activity resulting in a two-log reduction of viability counts at 50 µM. CATH-
1 reduced CFU/ml levels by two log units at 200 µM, while mCRAMP and LL-37 mixtures 
resulted in either a one log reduction, or no reduction at 200 µM concentrations in the 
presence of BLES. 
Similar results were seen against P. aeruginosa, where CATH-1, CATH-2, and LL-
37 peptides (in the absence of BLES) had MBC values from 5-10 µM (Figure 2.6), while 
mCRAMP reduced bacterial viability by three log units at 40 µM (Figure 2.6c). In the 
presence of BLES, CATH-2 again had a MBC of 200 µM, and a three-log reduction at 50 
µM. CATH-1 reduced P. aeruginosa viability by three log units at 200 µM. mCRAMP and 
LL-37 showed negligible bactericidal activity in BLES up to 200 µM concentrations. 
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Figure 2.5 
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Figure 2.5. Antimicrobial activities of cathelicidins against MRSA. a) CATH-1, b) CATH-
2, c) mCRAMP, and d) LL-37 in the absence (square, solid line) and presence (triangle, 
dotted line) of 10 mg/ml BLES against Methicillin-resistant Staphylococcus aureus WKZ-
2 in PBS after 3h at 37°C. (n=3) 
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Figure 2.6 
 
Figure 2.6. Antimicrobial assay of cathelicidin peptides against P. aeruginosa. a) CATH-
1, b) CATH-2, c) mCRAMP, and d) LL-37 in the absence (square, solid line) and presence 
(triangle, dotted line) of 10 mg/ml BLES against Pseudomonas aeruginosa VW178 in PBS 
after 3 h at 37°C. (n=3) 
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In vivo analysis of BLES+CATH-2 treatment 
The results of the experiment testing safety and tolerability are shown in Figure 2.7. 
The experiment focused on CATH-2 and included two control groups (air and saline 
instilled groups) and three experimental groups (CATH-2, BLES + CATH-2 and BLES 
instilled groups). Analysis of lung physiology included lung compliance and airway 
resistance (Figure 2.7a-b) which showed no significant difference among the groups. Mice 
that were instilled with CATH-2 alone had significantly higher protein content within the 
bronchoalveolar lavage fluid (BALF) versus animals in other treatment groups, and had 
significantly increased IL-6 levels versus animals treated with BLES alone (Figure 2.7c-d). 
BLES+CATH-2 treated animals showed no significant difference in protein or IL-6 levels 
when compared with air, saline, or BLES controls. Cell count analyses found no significant 
difference in total cell counts (Figure 2.7e) or neutrophil recruitment (Figure 2.7f) for any 
treatment group. 
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Figure 2.7 
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Figure 2.7. From in vivo tolerance model, a) compliance of the respiratory system, and b) 
airway resistance, as measured by FlexiVent; c) protein content, d) IL-6 content, e) total 
immune cells, and f) total number of recruited neutrophils obtained from animal BALF 
samples. (n=5-6) *p < 0.05. 
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2.4 Discussion 
The goal of the current study was to investigate the biophysical and antimicrobial 
properties of four novel surfactant/cathelicidin mixtures and to determine whether 
combining such elements together impacts native function. Four cathelicidin peptides were 
tested in combination with an exogenous surfactant, BLES. The presence of all cathelicidin 
peptides accelerated surface film formation of BLES as indicated by the spreading 
capabilities of BLES plus peptides over 600 seconds. While all other cathelicidin peptides 
decreased the ability of BLES to achieve low surface tensions during cyclic compressions 
on the CDS, the addition of CATH-2 to BLES had a minimal effect on the biophysical 
function of the exogenous surfactant even at high concentrations. AFM images suggested 
that the peptides did incorporate into the film and were capable of altering the film structure. 
Although there was mitigation of the bactericidal capabilities of BLES+CATH-2 when 
compared to CATH-2 activity alone, the BLES+CATH-2 compound could consistently 
reduce bacterial CFUs to below detectable levels, unlike all other surfactant/cathelicidin 
mixtures, which showed either a large decrease or complete loss of bactericidal function in 
the presence of BLES. Lastly, when intratracheally instilled into naïve mice, 
BLES+CATH-2 showed no effect on animal physiology, lung edema (as measured by 
protein leak), or IL-6 inflammatory response. Taken together, we conclude that it would be 
feasible to develop a surfactant/cathelicidin compound that is capable of maintaining 
surfactant and AMP properties and that, among the current peptides tested, BLES+CATH-
2 appears to be the most promising candidate for future studies to investigate the efficacy 
of this therapy as an antimicrobial treatment in vivo. 
78 
 
 
 
The overall rationale for our study was that surfactant can assist in the delivery of 
an antimicrobial peptide into the lung, thereby overcoming some of the limitations of local 
delivery of drugs in pulmonary bacterial infections. For such compounds to be effective, a 
direct interaction between the surfactant and the peptide would be essential to facilitate co-
distribution of the two compounds when delivered to the lung. Our data, including the AFM 
images of surfactant films and experiments related to the spreading of the surfactant 
indicate that such direct interaction occurs, as observed by the definitive changes in 
microdomain size and formation, particularly for CATH-1 and CATH-2 addition. The 
peptide-surfactant interaction is likely related to the amphipathic, cationic nature of 
cathelicidins, and their ability to interact with negatively charged phospholipids. 
Pulmonary surfactant contains approximately 10-15% acidic phospholipids, mainly 
phosphatidylglycerol (PG), with which the cathelicidins could electrostatically interact 
(23). Although surfactant composition is more complex than simple lipid mixtures, the idea 
of the interaction with PG is supported by studies by Sevcsik et al (24). This group utilized 
binary lipid mixtures to investigate interactions between lipid mixtures and LL-37, and 
found that even in binary mixtures the interaction between the cathelicidin and lipid mixture 
is dictated by one of the lipids present. Although the lipid ratios in their experimental model 
and those found within pulmonary surfactant are different, it is still reasonable to conclude 
that the interaction observed is between the cathelicidin peptides and PG since it appears 
this interaction with negatively charged phospholipids contributes to its basic mechanism 
of antimicrobial activity (2). We suggest that the interaction occurring between the 
surfactant phospholipids and cathelicidin peptides are affecting the individual properties of 
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each component, such as the surface tension reducing functions of BLES, and bactericidal 
capabilities of the cathelicidin peptides. 
Whereas the above discusses a general mechanism of interaction between 
cathelicidins and surfactant, we observed substantial variations among the peptides in terms 
of their behavior when mixed with surfactant. Specifically, marked differences were 
obtained when analyzing the antimicrobial activity when peptides were combined with 
BLES, with only CATH-2 maintaining a relatively robust activity. Differences were also 
observed in the microdomain shape and size via AFM when CATH-1 or CATH-2 were 
added to BLES, but this was not observed for mCRAMP or LL-37. Although those 
differences did not correlate with surfactant activity, these changes do provide evidence of 
direct interaction, and possibly incorporation, of the peptides in the surfactant film. Other 
studies have also found different lipid interactions among various AMPs. Studies by 
Neville et al (25) demonstrated that the addition of LL-37 to a monolayer of DPPG caused 
monolayer collapse at high surface pressures, but that addition of SMAP-29, a sheep 
cathelicidin, actually improved DPPG stability upon compression. This group suggested 
that this was due to the differences in peptide structures and hydrophobicity, and that 
SMAP-29 was more likely to interact with the head groups of the phospholipids, while LL-
37 was more likely to insert into the fatty acid groups of the lipid monolayers. This may 
help explain the differences observed within our study, as the peptides tested here have 
different structures. It is possible that CATH-2 interacts with PG similarly to SMAP-29, 
allowing CATH-2 to maintain its activity as more cationic residues are exposed to the 
external environment and able to interact with bacterial membranes. Other peptides, where 
the residues may be shielded by the interaction with the monolayer, would be less readily 
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available to interact with the targeted bacteria, and therefore have reduced bactericidal 
capabilities. One interesting feature of CATH-2 that could be related to this difference in 
activity is the presence of a proline residue at amino acid position 14 that forms a kink 
region between the two alpha-helical segments of the CATH-2 peptide. This kink is not 
present in the other tested AMPs. It was shown previously that this hinge region is essential 
for antibacterial activity since substitution of the proline residue, straightening the peptide, 
resulted in highly reduced activity (26, 27). Whether this structural difference between 
CATH-2 and the other AMPs is the basis of the observed differences in activity would be 
an interesting future investigation, and could potentially lead to the development of 
improved designer peptides for use in surfactant mixtures. 
It has been repeatedly shown that intratracheal surfactant administration results in 
better pulmonary distribution than aerosol and saline administration (28, 29). Exogenous 
surfactant has been shown to enhance the pulmonary delivery and bioavailability of other 
potential therapeutic agents such as anti-oxidants, antibiotics, corticosteroids and 
adenoviral vectors (8, 30). Similar to the current experiments, several studies have 
investigated the bactericidal and biophysical functions of antibiotics in the presence of 
exogenous surfactant. In general, it was found using in vitro techniques that some, but not 
all, of the antibiotics tested were inhibited in the presence of surfactant (31). A subsequent 
in vivo study in Klebsiella pneumoniae infected mice demonstrated that intratracheal 
administration surfactant with the antibiotic tobramycin had significantly reduced mortality 
compared to surfactant or tobramycin alone (32). These studies provide support for the 
concept of surfactant as a vehicle for drug delivery, including in the setting of bacterial 
infection. Our concept of utilizing AMP-based surfactant expands on these studies, as 
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cathelicidin peptides have the added advantage of lacking microbial resistance towards 
them, while maintaining broad-spectrum bactericidal functions against drug-resistant 
bacteria (2). 
Whereas the main focus of our in vitro experiments was the maintenance of 
surfactant and antimicrobial activities of potential AMP-based surfactant preparations, it 
should be noted that it has also been reported that AMP can have cytotoxic effects towards 
mammalian cells (26, 33, 34). Such effects could potentially limit the therapeutic 
applicability of this approach. Our in vivo experiment tested this issue for the most 
promising AMP-surfactant preparation, BLES+CATH-2, by instilling a therapeutic dose in 
healthy mice and assessing lung physiology and inflammation.  Consistent with the 
reported effects for AMP, instillation of CATH-2 by itself did result in slightly elevated 
lavage protein levels and IL-6 concentrations, indicative of mild pulmonary edema and 
inflammation. Importantly, no such deleterious effects were observed by administration of 
BLES+CATH-2. This data suggests that BLES+CATH-2 is well tolerated and safe when 
instilled in a healthy lung and that mild negative side-effects of the instillation of a high 
dose of CATH-2 by itself are mitigated by co-administration with surfactant. 
Although our main interpretation of our spreading data was that peptides did not 
inhibit this property of surfactant, it was interesting to note that the addition of all 
cathelicidin peptides actually improved the adsorptive function of surfactant, as seen by a 
reduced surface tension after 600 seconds, representing more surface-active material 
available at the air-liquid interface. Addition of all four peptides to exogenous surfactant 
led to significantly lower surface tension values reached after 600 seconds. It is possible 
that these findings are related to the ability of cathelicidin peptides to penetrate bacterial 
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membranes. In the context of surfactant this would imply that the peptides act as “bilayer 
breakers” thereby enhancing the ability of surfactant lipids to adsorb to the interface. This 
is similar to the proposed mechanisms by which the two hydrophobic surfactant proteins, 
SP-B and SP-C, are thought to enhance surfactant adsorption (35, 36). Interestingly, 
isolated SP-B has been reported to have antimicrobial activity as well (37). Although this 
activity was completely mitigated by the interaction with surfactant lipids, the finding does 
support the concept that there may be shared biophysical properties between AMPs and 
surfactant properties in terms of lipid interaction (38). 
In conclusion, our results support the proof of concept that AMP-based surfactant 
can be utilized for the therapy of bacterial infections. It appears that the interaction between 
cathelicidins and surfactant varies and among the four peptides tested, CATH-2 would be 
optimal for further testing. The current observations have been limited to in vitro studies, 
and in vivo safety studies.  Future studies are required to test the efficacy of this compound, 
by itself as well as in combination with other drugs, in an animal model of bacterial 
pneumonia. 
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Chapter 3: Administration of Pseudomonas aeruginosa 
killed by chicken cathelicidin-2 prevents lung 
inflammation in vivo   
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3.1 Introduction 
Pseudomonas aeruginosa is an opportunistic gram-negative bacteria, which is 
commonly found in patients with cystic fibrosis (CF), non-CF bronchectasis, ventilator-
associated pneumonia, or patients that are immunocompromised due to various underlying 
comorbidities (1–4). Treatment of P. aeruginosa airway infections, particularly in chronic 
disease states such as CF, are made difficult due to the emergence of antibiotic resistance 
(1, 5–7). Chronic infection by P. aeruginosa can lead to tissue injury, ultimately resulting 
in progressive lung dysfunction, respiratory failure, and death (8–12). Due to the increasing 
prevalence of antibiotic resistance, and the lack of new therapeutics being produced in the 
pharmaceutical pipeline (13), the development of novel antimicrobials to combat these 
infections are desperately needed. 
To address this issue, cathelicidins, a family of host defense peptides with direct 
antimicrobial activity, are being explored as potential alternatives for antibiotics. These 
peptides, which are endogenously produced by multiple cell types, including epithelial 
cells, macrophages, monocytes, and neutrophils, have a broad spectrum bactericidal 
activity and are less susceptible to classical mechanisms of bacterial resistance (14).  
Furthermore, cathelicidins exhibit a variety of immunomodulatory functions, which may 
provide additional benefits in their use to combat pulmonary infections (15).   
One specific cathelicidin, the chicken cathelicidin CATH-2, has previously been 
identified as a strong candidate for therapeutic use. This peptide has been demonstrated to 
kill P. aeruginosa in physiologically relevant conditions (16) and was shown to retain 
significant antimicrobial function when combined with a pulmonary surfactant vehicle for 
lung targeted delivery (17). Recent in vitro studies have demonstrated that the killing of 
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bacteria by CATH-2 can occur without inducing a marked inflammatory response (18, 19). 
This “silent killing” activity was demonstrated by incubating a macrophage cell-line with 
either CATH-2-, heat-, or antibiotic-killed Escherichia coli, or Salmonella enteritidis (19). 
Macrophages exposed to the bacterial products from either heat- or antibiotic-killed 
bacteria responded by producing high levels of inflammatory mediators such as IL-6 and 
TNF-α; as compared to the CATH-2-killed bacteria, which elicited minimal inflammatory 
cytokine production. Based on the clinical observations that chronic maladaptive 
inflammatory responses can lead to indiscriminate tissue damage and expedited lung injury, 
as observed in CF patients (19–22), this silent-killing property of CATH-2 may further 
extend its clinical potential.  
To date, silent killing by CATH-2 has only been observed in vitro. The in vivo 
environment within the lung is more complex as inflammation will involve multiple cell-
types, cell migration and activation, physiologic lung dysfunction, and a local inflammatory 
environment that may vary between different airways and alveoli. Therefore, the objective 
of the current study was to determine the role of CATH-2 in dampening the inflammatory 
response induced by killed bacteria in vivo. It is hypothesized that CATH-2-killed bacteria 
will elicit a reduced inflammatory response after in vivo intratracheal instillation as 
compared to heat and antibiotic killed bacteria. 
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3.2 Materials and Methods 
Preparation of killed bacteria for in vivo analysis 
An overnight culture of P. aeruginosa ATCC 27853 was diluted 1/10 in tryptic soy 
broth (TSB). The optical density was measured, and bacteria were further diluted in sterile 
saline to reach an initial concentration of approximately 2x106 CFU/ml. Subsequently, the 
bacteria were killed by CATH-2 (20 µM at 37°C for one hour), heat (90°C for one hour), 
or gentamicin (1 mg/ml gentamicin at 37°C for one hour). In a subset of bacteria killed by 
heat or gentamicin, 20 µM CATH-2 was added to the bacterial mixture before instillation. 
After intratracheal instillation, part of the bacterial solutions was plated via spot plating on 
tryptic soy agar (TSA), and incubated overnight at 37°C. The plates were examined the 
following morning to ensure complete bacterial killing. 
 
In vivo analysis following administration of killed bacteria 
Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 23-32 g, 
were used for this experiment. All animal procedures were approved by the Animal Use 
Subcommittee at the University of Western Ontario, and followed the approved guidelines 
described by the Canadian Council of Animal Care. Mice were anesthetized by 
intraperitoneal (IP) injection of ketamine (100 – 125 mg/kg body weight) and 
dexmedetomidine (0.5 mg/kg BW), and then intubated using a 20G catheter with the aid of 
a fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc., Houston, 
Texas, USA). Once intubated, mice were randomized into treatment groups and instilled 
with 50 µl of a) CATH-2-killed bacterial preparations, b) heat-killed bacteria, c) heat-killed 
bacteria supplemented with CATH-2, d) gentamicin-killed bacteria, e) gentamicin-killed 
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bacteria supplemented with CATH-2, or f) instilled with an air bolus (naïve controls). Mice 
were extubated following successful instillation and were allowed to breathe spontaneously 
for six hours. After six hours, the mice were euthanized by IP injection of sodium 
pentobarbital (110 mg/kgBW) and dissection of the descending aorta. The animals were 
placed on a FlexiVent© in order to measure lung compliance and elastance. Following 
these measurements, whole lung bronchoalveolar lavage fluid (BALF) was collected by 3 
x 1 ml aliquots of sterile saline. The whole lung lavage was immediately centrifuged at 400 
x g at 4°C for 10 minutes, and the pellet was collected for cell analysis, while the 
supernatant was collected and used to measure protein content, and cytokine analysis. A 
sample of the supernatant was centrifuged at 40 000 g at 4°C for 15 minutes, in order to 
separate pulmonary surfactant subfractions. Pulmonary surfactant concentrations were 
determined using a modified Duck-Chong assay as previously described (23). Total cell 
counts and differential cell analysis of the cells obtained in the lavage was done as 
previously described (24). Protein content of the lavage fluid was measured using a Micro 
BCA protein assay kit (Pierce, Rockford, Ill., USA), as per manufacturer’s instructions. 
Concentrations of mouse cytokines were measured using multiplexed immunoassay kits 
according to the manufacturers’ instructions (R&D Systems, Minneapolis, MN). A Bio-
Plex 200 readout system was used (Bio-Rad), which utilizes Luminex® xMAP fluorescent 
bead-based technology (Luminex Corporation, Austin, TX). Cytokine levels (pg/ml) were 
automatically calculated from standard curves using Bio-Plex Manager software (v. 4.1.1, 
Bio-Rad). 
 
Statistical Analysis 
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Analysis of the inflammatory response induced by killed bacteria were performed by one-
way measure analysis of variance (ANOVA) followed by Tukey post-hoc test.  Means were 
reported ± standard error of the mean.  Values were considered statistically significant at a 
probability value < 0.05. 
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3.3 Results 
Effect of killed bacteria administration on respiratory function 
 Six hours after receiving intratracheal instillation of killed bacteria, lung physiology 
was measured via FlexiVent. There was no significant difference between any of the 
treatment groups in any lung function measurements, including lung compliance, elastance, 
or total lung capacity (Table 3.1). Bronchoalveolar lavage fluid volumes were not 
significantly different between treatment groups (Table 3.2). Protein concentrations from 
lung lavage of animals receiving gentamicin-killed bacteria supplemented with CATH-2 
were significantly increased compared to naïve controls, but there was no significant 
difference among the other treatment groups (Table 3.2). 
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Treatment Group Weight (g) 
Lung Function 
Total Lung 
Capacity (ml) 
Compliance 
(ml/cmH2O) 
Elastance 
(cmH2O/ml) 
Naïve 29.5 ± 0.66 0.794 ± 0.041 0.0578 ± 0.0029 17.54 ± 0.92 
CATH-2-Killed 28.0 ± 1.40 0.752 ± 0.048 0.0529 ± 0.0041 19.41 ± 1.62 
Heat Killed 27.8 ± 0.72 0.777 ± 0.056 0.0558 ± 0.0033 18.14 ± 1.18 
Heat+CATH-2 27.8 ± 0.91 0.812 ± 0.034 0.0557 ± 0.0023 18.09 ± 0.73 
Gentamicin Killed 28.9 ± 0.65 0.862 ± 0.068 0.0581 ± 0.0031 17.51 ± 0.93 
Gent+CATH-2 27.8 ± 0.57 0.845 ± 0.031 0.0588 ± 0.0025 17.11 ± 0.71 
 
Table 3.1 Weight and lung function measurements of mice that were intratracheally 
administered killed bacteria. Values are expressed as mean ± SEM. (n=5-6) 
  
97 
 
 
 
Treatment 
Group 
Lavage 
Volume (ml) 
Surfactant Analysis 
Protein Content 
(mg/kgBW) Total Surfactant 
(mgPL/kg BW) 
Small Aggregate 
(mgPL/kg BW) 
Large Aggregate 
(mgPL/kg BW) 
Naïve 2.82 ± 0.07 8.82 ± 0.71 5.17 ± 0.45 3.23 ± 0.57 14.04 ± 0.72 
CATH-2 
Killed 
2.75 ± 0.09 8.82 ± 0.82 5.65 ± 0.34 3.14 ± 0.49 21.60 ± 3.72 
Heat Killed 2.88 ± 0.06 7.85 ± 0.22 3.87 ± 0.25 2.53 ± 0.35 14.44 ± 1.38 
Heat+ 
CATH-2 
2.66 ± 0.12 9.72 ± 1.04 5.17 ± 0.26 2.94 ± 0.77 16.63 ± 2.21 
Gentamicin 
Killed 
2.88 ± 0.07 9.12 ± 1.24 4.67 ± 1.04 3.24 ± 0.63 15.74 ± 2.53 
Gent+ 
CATH-2 
2.68 ± 0.14 7.94 ± 1.12 3.89 ± 0.58 2.73 ± 0.20 34.47 ± 9.56a 
 
Table 3.2 Lavage volume, surfactant analysis, and protein content from BALF of mice 
instilled killed bacteria. Values are expressed as mean ± SEM. (n=5-6) 
ap < 0.05 vs. naïve treatment group. 
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CATH-2-killed bacteria elicit reduced total cell counts and reduced neutrophil influx 
 Instillation of either heat-killed or gentamicin-killed bacteria caused a significant 
inflammatory response, with significant increases in total cells in the BALF compared to 
naïve animals (Figure 3.1). Pseudomonas aeruginosa killed by 20 µM of CATH-2 elicited 
a reduced inflammatory response. The number of cells recovered from the BALF of 
animals instilled with CATH-2-killed bacteria was a significantly reduced compared to 
gentamicin-killed bacteria. There was also a reduction in cell recruitment induced by 
CATH-2-killed bacteria compared to heat-killed bacteria that did not reach statistical 
significance.   
In addition to reducing total cell influx, the percentage of neutrophils in the BALF 
was also significantly reduced in animals treated with CATH-2-killed bacteria compared 
to both heat-killed and gentamicin-killed bacterial treatments (Figure 3.2).   
 
Addition of CATH-2 to heat-killed bacteria downregulates cell influx 
 Heat-killed P. aeruginosa that was supplemented with 20 µM CATH-2 after 
bacterial killing decreased the inflammatory response induced by heat-killed bacteria alone. 
There was a trend for reduced cellular influx between heat-killed and heat-killed+CATH-
2 treated animals (Figure 3.1), and the total cell counts for animals administered heat-killed 
bacteria + CATH-2 were similar to naïve treatment groups. Supplementation of CATH-2 
to gentamicin-killed bacteria did not have the same anti-inflammatory effect. There was no 
significant difference in total cell counts between gentamicin-killed bacteria and 
gentamicin-killed+CATH-2 treatment groups. 
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Similarly, the supplementation of CATH-2 to heat-killed bacteria induced a 
significant reduction in percentage of neutrophils in the BALF compared to heat-killed 
bacteria alone, reducing levels to the values observed in animals administered CATH-2-
killed bacteria (Figure 3.2). The percent of neutrophils recovered from gentamicin-
killed+CATH-2 treated animals were not reduced compared to gentamicin-killed bacteria 
(Figure 3.2). 
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Figure 3.1 
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Figure 3.1.  Total cells recovered from whole lung BALF of mice instilled killed bacteria. 
(n=5-6) *p < 0.05. 
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Figure 3.2 
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Figure 3.2. Percentage of neutrophil cells recovered from whole lung BALF of mice 
instilled killed bacteria. (n=5-6) *p<0.05; **p<0.01. 
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CATH-2-killed bacteria elicited reduced inflammatory cytokine release 
   Bacteria killed by CATH-2 induced significantly less cytokine release compared 
to both heat-killed and gentamicin-killed bacteria. Levels of TNF-α, IL-6, and KC were 
significantly reduced in the BALF of animals receiving CATH-2-killed bacteria compared 
to animals receiving either heat- or gentamicin-killed bacteria, and IL-12p70, G-CSF, MIP-
2, IL-23p19, and MMP-9 were significantly reduced compared to animals administered 
gentamicin-killed bacteria alone (Figure 3.3). 
 Similar to cellular influx data, the addition of CATH-2 to heat-killed bacteria was 
able to reduce the inflammatory cytokine production induced by heat-killed bacteria. 
Levels of TNF-α and KC were significantly reduced compared to the heat-killed bacteria 
group alone, while reduction trends persisted for the majority of inflammatory cytokines. 
On the other hand, there was no significant difference between animals administered 
gentamicin-killed bacteria supplemented with CATH-2 and gentamicin-killed bacteria 
alone in many cytokines, including TNF-α, KC, IL-12p70, G-CSF, MIP-2, or MMP-9. In 
fact, IL-6 and IL-23p19 showed increases in release from animals administered gentamicin-
killed+CATH-2 compared to gentamicin-killed bacteria alone (Figure 3.3). 
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Figure 3.3 
TNF-  Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0.0
2.5
5.0
25
75
125
175
*
***
*
N.DT
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
IL-6 Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
500
1000
1500
2000
2500
*
***
***
IL
-6
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
KC (CXCL1) Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
500
1000
1500
2000
N.D
*
***
*
***
K
C
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
G-CSF Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
200
400
600
800
1000
1200 ***
***
***
G
-C
S
F
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
IL-12p70 Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
5
10
15
N.D N.D N.D
***
*
**
IL
-1
2
p
7
0
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
IL-23p19 Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
100
200
300
*
***
N.D N.D
**
IL
-2
3
p
1
9
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
MIP-2 Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
200
400
600
800
1000
**
**
Treatment
M
IP
-2
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
MMP-9 Concentration
N
ai
ve
C
A
TH
-2
H
ea
t
H
ea
t+
C
A
TH
-2
G
en
ta
m
ic
in
G
en
t+
C
A
TH
-2
0
20000
40000
60000
80000
100000 *
Treatment
IL
-2
3
p
1
9
 C
o
n
c
e
n
tr
a
ti
o
n
(p
g
/m
l)
 
Figure 3.3.  Cytokine and chemokine concentrations from whole lung BALF. (n=5-6) 
*p<0.05; **p<0.01; ***p<0.001. 
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3.4 Discussion 
 In this study, we have shown that CATH-2 is able to kill a clinically-relevant lung 
pathogen, P. aeruginosa, and intratracheal instillation of these killed bacteria does not 
induce a marked inflammatory response, as observed with heat or conventional antibiotic 
killed bacteria. Compared to other methods of bacterial killing, the bacteria killed by this 
cathelicidin peptide induced a significantly dampened inflammatory response after 
instillation, through the reduced recruitment of leukocytes and decreased concentrations of 
pro-inflammatory cytokines in the lavage fluid. Furthermore, the addition of CATH-2 to 
heat-killed bacteria eliminated the exacerbated inflammatory response induced by heat-
killed bacteria, although this anti-inflammatory effect was not observed with gentamicin-
killed bacteria.   
To address our hypothesis that CATH-2-killed bacteria will elicit a reduced 
inflammatory response after in vivo intratracheal instillation, we utilized a model of 
intratracheal instillation of killed bacteria into healthy mice. None of the experimental 
groups showed any sign of lung dysfunction as indicated by measurements of compliance, 
elastance, surfactant composition, as well as total protein in the lavage. This data suggests 
that the inflammatory responses measured in this experiment were in response to the 
instilled bacterial products and peptide, and not an indirect effect due to tissue injury within 
the lung. The use of killed bacteria allowed for the investigation of CATH-2’s ability to 
modulate the inflammatory responses induced by products released after bacterial death, 
without the confounding factors associated with toxin production or epithelial damage 
induced by live bacteria (3, 11). Therefore, this provides evidence for the role of 
cathelicidin peptides in modulating immunity and inflammatory responses after bacterial 
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clearance, as observed through the changes in cell recruitment and inflammatory cytokine 
production.    
The main finding of this study is that the mechanism of bacterial death affected the 
inflammatory response in vivo. While heat-killed and gentamicin-killed bacteria were able 
to induce robust inflammatory responses, CATH-2-killed bacteria induced a significantly 
lower inflammatory response, as fewer neutrophils were recruited, and the concentration 
of inflammatory cytokines recovered from the BALF was significantly lower for multiple 
different markers. CATH-2’s ability to kill bacteria without inducing an inflammatory 
response has previously only been documented in vitro, as it was shown that treatment of 
macrophages with peptide-killed E. coli, S. enteritidis, or P. aeruginosa exhibit a reduced 
inflammatory response after co-incubation (19). Our data provides clear evidence that this 
phenomenon also occurs in the multicellular in vivo environment within the lung. Taken 
together, these studies strongly support the conclusion that the cathelicidin peptide CATH-
2 can not only kill bacteria directly, but is also able to dampen the immunogenic response 
induced by the bacterial components, such as endotoxins and other bacterial structures, 
released upon bacterial cell death.  
A second important finding of this study was the ability of CATH-2 to down-
regulate the inflammatory responses caused by heat-killed bacteria. The fact that CATH-2 
supplementation was able to return inflammation to basal levels adds evidence of the ability 
of CATH-2 to directly modulate the inflammatory response induced by bacterial products, 
and that this effect is can be independent from its killing activity. However, this down 
regulation was not observed when CATH-2 was supplemented to gentamicin-killed 
bacteria, where in fact an exacerbated inflammatory response was observed. While 
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gentamicin has been mainly studied in nephrotoxicity and ototoxicity due to its common 
side effects, the mechanisms of action to induce both apoptosis and necrosis in vivo involve 
the accumulation of high levels of gentamicin intracellularly, causing non-specific 
activation of multiple apoptotic and necrotic pathways (25). It is possible that the high 
concentration of gentamicin (1 mg/ml) that was used to kill the bacteria induced some of 
these cytotoxic effects once administered intratracheally. Recent studies in our lab have 
demonstrated that bacteria killed with a lower dose of gentamicin induced inflammatory 
effects that were downregulated by co-administration of CATH-2, similar to heat-
killed+CATH-2 observations (Brandon Baer, unpublished results). Overall, these results 
require further investigation into the mechanism of action, in order to understand the 
potential of cathelicidins as active therapeutics in co-treatment with conventional 
antibiotics.  
Initial interest in cathelicidins for therapeutic development focused solely on their 
direct bactericidal functions (26, 27). CATH-2 has been repeatedly shown to possess 
bactericidal activity against multiple different bacterial strains under a wide variety of 
environmental conditions in in vitro settings (28–31). Unlike other cathelicidin peptides, 
such as human LL-37, which lose bactericidal activity under physiologic salt conditions 
(32), CATH-2 appears to be relatively insensitive to a variety of different conditions, 
including serum and high ionic environments. The ability of CATH-2 to maintain 
bactericidal activity provides evidence for its potential direct bactericidal role in vivo (16, 
17). Regardless of their degree of bactericidal activity, it is abundantly clear that 
cathelicidin peptides can be directly responsible for the clearance of bacterial infection, and 
that a loss/decrease in peptide can lead to a strong reduction in immune response and 
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bacterial clearance (33, 34). From the data presented here, we suggest that CATH-2 has the 
ability to both kill bacteria, as well as dampen inflammatory responses after stimulation 
with the bacterial products. This direct bactericidal activity along with the ability to inhibit 
the inflammatory response induced by killed bacteria is key in regulating proper immune 
responses. These regulatory functions prevent excessive inflammatory responses, and 
indiscriminate cytotoxic damage caused by neutrophil migration and activation, commonly 
associated with chronic infection states (35–38).    
One of the common immunomodulatory functions of various cathelicidin peptides 
is their (relatively) conserved ability to bind and neutralize bacterial endotoxins, such as 
LPS, thereby silencing the downstream inflammatory signalling process (39–41). In 
combination with these previous observations, our results suggest that, in addition to 
CATH-2 direct antimicrobial activity via bacterial membrane binding and cell lysing, there 
is a potential anti-inflammatory activity of CATH-2 via binding to the LPS released from 
the bacterial membrane, thereby inhibiting cellular activation through TLR 4. Additional 
studies have also shown that cathelicidins are able to down-regulate signalling through 
other TLR pathways such as TLR 5 (42). As P. aeruginosa contains flagellin, the main 
agonist of TLR 5, it is possible that CATH-2 has some immunomodulatory interaction with 
this pathway as well, similar to that observed with other cathelicidin peptides. 
In a natural host immune response, activation of TLRs by bacterial by-products 
elicits a series of complex intracellular cascades, with the focus on translocation and 
activation of the nuclear factor-κB (NF-κB) (43). This transcription factor is found in all 
major cell types, and is one of the transcription factors responsible for this pro-
inflammatory cytokine release (44, 45). The goal of most inflammatory cytokines released 
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is the recruitment of circulating neutrophils to aid in the removal of an invading pathogen 
(46). However, in patients with underlying diseases, such as cystic fibrosis, this recruitment 
can be detrimental as neutrophils release a vast array of toxins and oxidizers, which act to 
kill bacteria, but can damage host tissues in the process (47). The ability of CATH-2 to 
prevent this signalling caused by bacterial debris, which is found throughout the CF airways 
over the course of a patient’s life, would therefore be able to protect tissue damage caused 
by the exacerbated inflammatory response often observed (47). 
The ability to both kill clinically-relevant pathogens, as well as reduce the ensuing 
inflammatory environment, are essential properties for the development of CATH-2 as a 
therapeutic in cystic fibrosis. The CF microenvironment is incredibly complex, and is 
marred by the combination of a non-functional mucociliary elevator (22), incompetent 
innate immune responses (47), ineffective removal of apoptotic cells and debris (48), all 
cumulating in a tissue-damaging pro-inflammatory environment (47, 49, 50). Therefore, 
these studies provide evidence for the potential therapeutic use of CATH-2 in the treatment 
of P. aeruginosa infection in CF patients. Based on these experiments, CATH-2 may be 
developed in order to both reduce the bacterial load via direct bactericidal activity, as well 
as minimize the inflammatory impact of the bacterial debris after death. These two 
properties could make CATH-2 a powerful future therapeutic option in the treatment of 
CF-associated pneumonia.   
In conclusion, CATH-2 is an effective bactericidal agent, and bacteria killed 
through this peptide result in a diminished inflammatory response in vivo, presumably 
enabling the host organism to prevent an inflammatory environment after the colonizing 
bacteria are cleared. This anti-inflammatory role adds merit to cathelicidins’ potential as 
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therapeutic antimicrobial agents in the future. However, their pro-inflammatory role with 
bacteria and conventional antibiotics raises questions as to the mechanism of interaction 
between these compounds, and requires further investigation before the two can be used 
effectively together. 
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Chapter 4: The antibacterial and anti-inflammatory 
activity of an exogenous surfactant preparation fortified 
with chicken cathelicidin-2 against cystic fibrosis 
associated pathogens 
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4.1 Introduction 
Cystic fibrosis (CF) is an autosomal recessive disease caused by defects in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene, which leads to alterations in 
the respiratory epithelial cilia and increased viscosity of the airway-surface mucosal layer. 
As a consequence of the inability to efficiently clear airway secretions, chronic airway 
colonization of bacterial pathogens ensues, resulting in a vicious circle of repeated lower 
respiratory tract infections, inflammation and tissue remodelling (1, 2). The prolonged use 
of oral or systemic antibiotics used to treat infections in these patients frequently results in 
airway colonization of multi-drug resistant bacteria, which represents an independent 
predictor of adverse clinical outcomes, decline in lung function and death (2–4). In 
addition, the complex pro-inflammatory environment induced by chronic bacterial airway 
infections further promotes airway epithelial cell injury and airway remodelling (5–11). 
Over time, the development of antibiotic-resistant bacterial infections coupled with, 
chronic, maladaptive inflammation poses a significant therapeutic challenge. Novel 
therapies are urgently needed in order to improve the quality of life for this challenging 
patient population.   
Cathelicidins are a class of host-defense peptides that have been investigated for 
their potential therapeutic use against antibiotic-resistant infections (12). Cathelicidins are 
essential components of the innate immune system that are highly conserved across 
multiple mammalian species and have been shown to possess both direct bactericidal 
activity and immunomodulatory activity including alterations of inflammatory cytokine 
production and immune cell migration (13–21). Due to their broad-spectrum antimicrobial 
and immunomodulatory effects, these peptides may represent an excellent alternative to 
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conventional antimicrobials and are currently being investigated for use in patients with CF 
(22–25). 
In order to optimize the delivery of therapeutics throughout the airways, exogenous 
surfactant has been investigated as a potential delivery vehicle due to its ability to improve 
distribution of lung targeted therapeutics to peripheral lung regions (26–28). The use of 
exogenous surfactant has been thoroughly investigated and currently exists as the standard 
of care for neonates with surfactant deficiency in the setting of neonatal respiratory distress 
syndrome, and is therefore safe and well tolerated (26, 28, 29). Our group has previously 
investigated a combined approach using a chicken cathelicidin, CATH-2, together with a 
commercially available exogenous surfactant preparation, bovine lipid-extract surfactant 
(BLES), and has shown that BLES+CATH-2 maintains both excellent surfactant 
biophysical properties, antimicrobial activity, and was tolerated  when administered 
intratracheally to naïve mice (30). Therefore, the objective of the current study was to assess 
the specific antimicrobial or anti-inflammatory properties of BLES+CATH-2 for the 
treatment of CF related lung infections. It was hypothesized that BLES+CATH-2 will 
exhibit bactericidal activity against multi-drug resistant bacteria obtained from CF patients 
and additionally, that BLES+CATH-2 will reduce the inflammatory response induced by 
bacterial products in an in vivo model of pulmonary inflammation. 
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4.2 Materials and Methods 
Clinical isolates 
 Clinical bacterial isolates were obtained from nine adult CF patients attending the 
London Health Sciences Centre outpatient CF clinics and protocols were approved by the 
Human Ethics subcommittee at The University of Western Ontario. Isolated bacteria were 
stored in citrate glycerol solutions at -80°C, and were isolated, identified and sub-cultured 
onto chocolate blood agar (CBA) prior to use in study. The samples obtained included eight 
P. aeruginosa, one A. xylosoxidans, and three S. aureus bacterial strains isolated from CF 
sputum samples. Antibiotic sensitivities of the isolated bacteria were obtained according to 
Clinical Laboratory Standards Institute procedures.   
 
Bactericidal activity against clinical bacteria 
 Bactericidal activity was measured using a spot plating assay.  In brief, an overnight 
culture of bacteria grown in TSB diluted in Müeller-Hinton Broth (MHB). The turbidity 
was adjusted to 0.5 McFarland, followed by an additional 50x dilution in either MHB or 
saline. Subsequently, 50 µl of bacteria and 50 µl of either CATH-2 or BLES+CATH-2 (0-
200 µM of CATH-2; 10 mg/ml phospholipid of BLES) was added to a polypropylene 
coated 96-well plate, and incubated at 37°C for three hours with no shaking.  After 
incubation, the bacterial suspension was serially diluted 10-10 000-fold, and 10 µl of each 
dilution was spot plated in triplicate on CBA plates. These plates were incubated overnight, 
and colonies on the plates were counted the following morning. Minimum bactericidal 
concentration (MBC) was determined as the minimum CATH-2 concentration at which no 
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bacterial growth was observed, corresponding to a bacterial concentration of less than 100 
CFU/ml.   
 
In vivo antimicrobial-independent inflammation model  
One mucoid strain of P. aeruginosa (Patient 6) and one S. aureus (Patient 4) (Table 
4.1) species were selected for use in this study. An overnight culture of P. aeruginosa or S. 
aureus was diluted 1/10 in MHB. The optical density was measured using a 
spectrophotometer, and bacteria were further diluted in MHB to reach an initial 
concentration of approximately 2x106 CFU/ml.  Subsequently, the bacteria were killed by 
heat (90°C for one hour). In a subset of bacteria killed by heat, CATH-2 (20 µM) or 
BLES+CATH-2 (10 mg/ml phospholipid; 100 µM peptide) was added to the killed-bacteria 
mixture prior to instillation. The dead-bacteria solutions were plated via spot plating on 
chocolate agar, and incubated overnight at 37°C to confirm complete bacterial killing of 
instilled samples. 
The killed bacteria were then instilled into male C57Bl/6 mice (Charles River, 
Sherbrooke, Qc, Canada) as previously described in Chapter 3. Once intubated, mice were 
randomized to receive a 50 µl instillation of either heat-killed bacteria, heat-killed bacteria 
+ CATH-2, heat-killed bacteria + BLES+CATH-2, or MHB without bacteria as a negative 
control. Mice were extubated following successful instillation, followed by a subcutaneous 
injection of 0.5 ml of saline and were allowed to breathe spontaneously for six hours. 
Following the 6-hour time period, the mice were euthanized by sodium pentobarbital 
overdose (110 mg/kgBW) and severance of the descending aorta, and were placed on a 
FlexiVent© to measure quasi-static lung compliance and elastance. Following Flexivent 
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measurements, whole lung bronchoalveolar lavage fluid (BALF) was collected by flushing 
the lungs with 3 aliquots of 1 ml sterile saline. The whole lung lavage was immediately 
centrifuged at 400 x g at 4°C, and the pellet was collected for cell analysis, while the 
supernatant was collected and used to measure protein content and cytokine quantification. 
Differential cell analysis of the cell pellets obtained from the lavage was done as 
previously described (31). Protein content of the lavage fluid was measured using a Micro 
BCA protein assay kit (Pierce, Rockford, Ill., USA), according to the manufacturer’s 
instructions. Concentrations of mouse cytokines were measured using multiplexed 
immunoassay kits according to the manufacturers’ instructions (R&D Systems, 
Minneapolis, MN). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes 
Luminex® xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). 
Cytokine levels (pg/ml) were automatically calculated from standard curves using Bio-Plex 
Manager software (v. 4.1.1, Bio-Rad). 
 
Statistical Analysis 
 Analysis of the inflammatory response induced by heat-killed P. aeruginosa and S. 
aureus was performed by a one-way measure of variance (ANOVA) followed by Tukey 
post-hoc test.  Means were reported ± standard error of the mean, and values were 
considered statistically significant at a probability value (p) < 0.05. 
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4.3 Results 
Patient Data 
 In vitro bacterial-resistance patterns were obtained using protocols performed by 
the London Health Science Centre Clinical Microbiology Laboratory and clinical 
characteristics of cystic fibrosis patients are shown in Table 4.1. Patients ranged between 
24 and 57 years of age.  Severity of disease was variable between patient groups, with 
FEV1PRED between 28 and 87%. Two-thirds of patients were colonized with at least one 
strain of P. aeruginosa, 3 out of the 9 patients were infected with S. aureus, and one patient 
was infected with A. xylosoxidans. Of the eight P. aeruginosa isolates investigated, 50% 
presented with a mucoid phenotype. Of all bacteria investigated, 58% were resistant to at 
least two conventional antibiotics. Bacterial resistance did not correlate with age, or disease 
severity. 
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Patient No. Sex (M/F) Age (years) Weight (kg) BMI (kg/m2) FEV1 %Pred Bacteria Resistance Profiles 
1 F 57 60.6 22.5 39 Pseudomonas aeruginosa NR 
2 M 24 72 25.3 50 Staphylococcus aureus Clindamycin, Erythromycin R 
3 M 50 57 19.3 43 Achromobacter xylosoxidans 
Gentamicin, Meropenem, 
Tobramycin R; Imipenem, 
Ciprofloxacin I 
4 F 35 62 22.4 87 Staphylococcus aureus NR 
      Pseudomonas aeruginosa (muc) NR 
      Pseudomonas aeruginosa Tobramycin, Gentamicin R 
5 F 44 59 22 73 Pseudomonas aeruginosa (muc) 
Amikacin, Gentamicin, 
Meropenem, Ciprofloxacin, 
Tobramycin R 
6 F 40 57 20.9 52 Pseudomonas aeruginosa (muc) Gentamicin, Tobramycin R 
7 M 37 52.5 19.3 28 Pseudomonas aeruginosa (muc) NR 
8 M 27 62 18.7 48 Staphylococcus aureus 
Clindamycin, Erythromycin, 
Cloxacillin R 
9 F 31 40.5 18.2 55 Pseudomonas aeruginosa (muc) NR 
            
Pseudomonas aeruginosa 
Meropenem R; Ciprofloxacin, 
Gentamicin I 
 
Table 4.1.  Resistance profiles of clinical samples. Resistance profiles were obtained by London Health Sciences Centre Clinical 
Microbiology Laboratory using clinical laboratory and standards institute protocols.  Muc = mucoid phenotype.  NR = no resistance 
identified, R = resistant, I = impaired activity. 
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Bactericidal activity of BLES+CATH-2 against bacteria from cystic fibrosis patients 
After in vitro incubation of either CATH-2 or BLES+CATH-2 with the isolated 
bacteria, it was observed that CATH-2 alone exhibited potent bactericidal activity against 
all P. aeruginosa strains tested, regardless of antibiotic resistance profile of the bacteria 
(Figure 4.1). The MBC of CATH-2 against all P. aeruginosa strains was between 2.5 – 10 
µM. BLES+CATH-2 bactericidal activity against the clinical P. aeruginosa was much 
more variable, with bacterial recovery varying between a 3-log reduction to complete 
bacterial killing. Overall, BLES+CATH-2 MBC values were typically 100 µM, and as low 
as 50 µM against select CF-derived isolates (Figure 4.1). 
 Similar to P. aeruginosa, CATH-2 exhibited potent antimicrobial activity against 
all strains of S. aureus tested. CATH-2 again showed bactericidal activity against all S. 
aureus isolates investigated, with MBC values between 5 – 10 µM for all strains 
investigated (Figure 4.2). BLES+CATH-2 showed consistent bactericidal activity, and 
achieved MBC values at 100 µM against all S. aureus isolates tested. Bactericidal activity 
of CATH-2 and BLES+CATH-2 against A. xylosoxidans was similar to activity observed 
against both P. aeruginosa and S. aureus (Figure 4.3). 
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Figure 4.1 
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Figure 4.1.  Antimicrobial assays of CATH-2 and BLES+CATH-2 against P. aeruginosa 
isolates.  The bacteria were suspended in MHB, and then treated with various 
concentrations of CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml 
phospholipid of BLES (red, dotted line). (n=3) 
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Figure 4.2 
 
 
Figure 4.2. Antimicrobial assays of CATH-2 and BLES+CATH-2 against S. aureus 
isolates. The bacteria were suspended in MHB, and then treated with various concentrations 
of CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES 
(red, dotted line). (n=3) 
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Figure 4.3. 
Patient 3 - A. xylosoxidans
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Figure 4.3. Antimicrobial assays of CATH-2 and BLES+CATH-2 against A. xylosoxidans. 
The bacteria were suspended in MHB, and then treated with various concentrations of 
CATH-2 (green, solid line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES (red, 
dotted line). (n=3) 
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Bactericidal activity of CATH-2 and BLES+CATH-2 in saline 
 Figure 4.4 demonstrates the bactericidal activity of CATH-2 and BLES+CATH-2 
in saline against the same CF-derived bacteria used above. Against P. aeruginosa, CATH-
2 was an effective antimicrobial agent, and was able to reduce bacterial recovery to below 
detectable levels at concentrations between 5-10 µM. The addition of BLES severely 
inhibited bactericidal activity, as BLES+CATH-2 was unable to reduce any strain of 
bacteria to below detectable levels, even at 100 µM concentrations.  
 CATH-2 possessed minimal bactericidal activity against either S. aureus or A. 
xylosoxidans, as it was only able to reduce bacteria to below detectable levels in one strain 
(Patient 8 S. aureus) at a concentration of 50 µM. While increasing doses of CATH-2 were 
able to reduce some bacterial recovery (2-3 log reduction), BLES+CATH-2 exhibited no 
detectable bactericidal activity against any isolates of S. aureus or A. xylosoxidans. 
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Figure 4.4 
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Figure 4.4. Representative antimicrobial assays of CATH-2 and BLES+CATH-2 against 
various bacterial species isolated from CF patient sputum in saline. The bacteria were 
suspended in saline, and then treated with various concentrations of CATH-2 (green, solid 
line) or CATH-2 suspended in 10 mg/ml phospholipid of BLES (red, dotted line). (n=3) 
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In vivo inflammation induced by killed cystic fibrosis derived bacteria 
To investigate the potential anti-inflammatory effects of BLES+CATH-2, we used 
a previously reported model of inflammation induced by killed bacteria as described in 
Chapter 3. After instillation of the killed bacteria, there were no significant differences in 
lung compliance, elastance or protein content found within the lungs of instilled animals 
(Table 4.2). We observed a significant increase in total cell counts recovered in the BALF 
from animals that received intratracheally-administered heat-killed P. aeruginosa 
compared to control treatments (Figure 4.5a). We demonstrated that there was no increase 
in total cells recovered from animals administered CATH-2-killed P. aeruginosa compared 
to animals that did not receive killed bacteria. The differential cell counts demonstrated a 
significant increase in neutrophils from animals administered heat-killed P. aeruginosa 
compared to control animals, which was not observed in animals administered CATH-2-
killed bacteria (Figure 4.5b). Supplementation of heat-killed P. aeruginosa with either 
CATH-2 or BLES+CATH-2 significantly reduced total cells in the BALF, including 
significantly lower number of neutrophils compared to heat-killed control groups (Figure 
4.5a). These values for heat-killed bacteria supplemented with CATH-2 or with 
BLES+CATH-2 groups were not significantly different from the control group, or animals 
receiving CATH-2-killed bacteria alone (Figure 4.5b). Multiplex cytokine analysis showed 
that heat-killed P. aeruginosa elicited a significant increase in KC, MIP2, and GM-CSF 
compared to controls, while CATH-2-killed bacteria did not (Figure 4.6). Heat-killed P. 
aeruginosa supplemented with either CATH-2 or BLES+CATH-2 did not increase any of 
the inflammatory cytokines measured compared to negative controls, and significantly 
decreased KC concentrations compared to heat-killed bacteria. BLES+CATH-2 
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supplementation also significantly reduced MIP-2 levels compared to heat-killed P. 
aeruginosa. 
For S. aureus, cell counts recovered from mice administered heat-killed bacteria 
were significantly higher than the negative control group (Figure 4.7a). Cell counts from 
animals administered CATH-2-killed S. aureus were not statistically different from control 
animals, but was not statistically different compared to animals receiving heat-killed 
bacteria. Heat-killed bacteria supplemented with CATH-2 or BLES+CATH-2 were 
significantly reduced compared to heat-killed alone (Figure 4.7a). Heat-killed S. aureus 
supplemented with CATH-2 or BLES+CATH-2 also had a significantly lower recovery of 
neutrophils compared to heat-killed bacteria alone (Figure 4.7b). Despite the differences in 
cells recovered and cell differentials, there was no increase in any cytokine production after 
administration of heat-killed S. aureus compared to the control treatment, and no significant 
difference in any cytokine investigated for animals administered killed S. aureus (Figure 
4.8).   
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Treatment 
Protein Content 
(mg/kg BW) 
Quasi-Static 
Compliance 
(ml/cmH2O) 
Quasi-Static 
Elastance 
(cmH2O/ml) 
Control 21.62 ± 3.0 0.0777 ± 0.016 13.28 ± 2.70 
P. aeruginosa    
Heat-killed 20.56 ± 9.7 0.0718 ± 0.0080 14.08 ± 1.76 
CATH-2-killed 24.80 ± 8.2 0.0676 ± 0.0071 14.92 ± 1.55 
Heat+CATH-2 19.44 ± 5.9 0.0755 ± 0.0069 13.35 ± 1.34 
Heat+(BLES+CATH-2) 17.58 ± 4.9 0.0801 ± 0.0064 12.56 ± 1.07 
S. aureus    
Heat-killed 20.79 ± 5.2 0.0754 ± 0.0132 13.70 ± 3.02 
CATH-2-killed 22.08 ± 4.4 0.0739 ± 0.0066 13.62 ± 1.24 
Heat+CATH-2 20.98 ± 7.8 0.0736 ± 0.0080 13.74 ± 1.64 
Heat+(BLES+CATH-2) 18.39 ± 8.0 0.0712 ± 0.0071 14.16 ± 1.46 
 
Table 4.2. Protein content obtained from BALF after whole lung lavage, and quasi-static 
compliance and elastance as measured by FlexiVent. Values presented as mean ± SEM. (n=5-
7) 
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Figure 4.5 
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Figure 4.5. Cell counts and differentials cell counts of animals administered heat-killed P. 
aeruginosa obtained from Patient 6. a) Total cell counts obtained from BALF of animals 
administered killed bacteria. b) Macrophage and neutrophil concentrations obtained from 
BALF of animals administered killed bacteria. (n=4-7) *p < 0.05, **p < 0.01, ***p < 0.001 
vs. control; ###p < 0.001 vs. heat-killed bacteria.  
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Figure 4.6 
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Figure 4.6. Cytokine content in the BALF obtained from animals administered killed P. 
aeruginosa. (n=5-7) *p < 0.05 vs. control; ##p < 0.01 vs. heat-killed.  
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Figure 4.7 
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Figure 4.7. Cell counts and differentials of animals administered heat-killed Patient 4 S. 
aureus. a) Total cell counts obtained from BALF of animals administered killed bacteria. 
b) Macrophage and neutrophil concentrations obtained from BALF of animals 
administered killed bacteria. (n=5-6) *p < 0.05, **p < 0.01 vs. control; ##p < 0.01, ###p < 
0.001 vs. heat-killed bacteria; +p < 0.05 vs. CATH-2-killed bacteria. 
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Figure 4.8 
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Figure 4.8.  Cytokine content in the BALF obtained from animals administered killed S. 
aureus. (n=6-7)  
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4.4 Discussion 
In the current study, the antimicrobial and anti-inflammatory effects of 
BLES+CATH-2, a chicken cathelicidin suspended in a clinically-used exogenous 
surfactant, were investigated as a potential therapeutic compound for the treatment of cystic 
fibrosis. Here, we provided evidence that BLES+CATH-2 exhibits bactericidal activity 
against an array of clinically derived pathogens from adult cystic fibrosis patients, as well 
as being able to reduce the recruitment of inflammatory cells and modulate 
proinflammatory cytokine production after heat-killed pathogens were instilled in vivo. 
Taken together, the bactericidal and immunomodulatory properties of BLES+CATH-2 
represent a potential therapy that warrants further investigation for the treatment of cystic 
fibrosis lung infections. 
The first goal of this study was to identify the bactericidal potential of 
BLES+CATH-2 against multiple cystic fibrosis-associated bacterial isolates, including 
multi-drug resistant isolates. P. aeruginosa represents one of the most prevalent bacteria 
found in CF patients, while S. aureus is the most common bacteria in patients under the age 
of 18 (8, 32–36). In addition to being the most common bacteria, these are also the most 
drug-resistant bacteria isolated from CF patients, with reports of resistance rates as high as 
22.6% and 42.7% against select antibiotics for both S. aureus and P. aeruginosa 
respectively (37, 38). Consistent with this information, the multiple strains of P. aeruginosa 
(including both mucoid and non-mucoid phenotypes), S. aureus, and A. xylosoxidans 
isolated from CF patient sputum samples displayed a wide range of antibiotic resistance 
patterns. Although the antimicrobial activity of BLES+CATH-2 against these clinical 
strains was reduced compared to the CATH-2 peptide alone, BLES+CATH-2 exhibited 
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significant antimicrobial activity at higher CATH-2 concentrations. At 100 µM peptide 
concentrations, BLES+CATH-2 was able to reduce eight out of twelve bacterial isolates to 
below detectable levels after three-hour incubations. For the remaining bacteria tested, 
BLES+CATH-2 was still able to reduce bacteria by 3 log values for two of the four isolated 
strains. This data was similar to what was previously observed when BLES+CATH-2 was 
tested against other strains of P. aeruginosa or S. aureus (30). The concentration of 100 
µM in the BLES+CATH-2 compound was the concentration previously used in safety and 
tolerability studies in Chapter 2, suggesting that this concentration would be effective as 
a therapeutic. 
Interestingly, CATH-2 exhibited minimal bactericidal activity against S. aureus 
when suspended in saline, but was significantly more active when the bacteria were 
suspended in Müeller-Hinton broth. Previous groups have also shown this disparity in 
activity, albeit during investigations of different peptides and different bacteria (39). They 
determined that the key component of media that was responsible for these differences in 
activity was carbonate, which appeared to increase bacterial susceptibility via alterations 
in the membrane thickness. It is possible that similar changes occurred in this study, which 
would explain the increased sensitivity of S. aureus to CATH-2, and the enhanced 
antimicrobial activity of BLES+CATH-2 against both S. aureus and P. aeruginosa 
suspended in MHB as opposed to saline. Importantly, it is suggested that the MHB media 
conditions may be more accurate measures of antimicrobial activity. First, the Clinical and 
Laboratory Standards Institute guidelines for investigations of antibiotic efficacy are 
performed in MHB, and therefore our results presented here are directly applicable to 
clinical investigation guidelines (40). Secondly, due to the carbonate and bicarbonate 
139 
 
 
 
content found naturally within the lung, we believe that these media conditions are more 
relevant to the in vivo environment, supporting the potential in vivo antimicrobial activity 
of CATH-2 and BLES+CATH-2. Interestingly, as the CFTR is also a bicarbonate 
transporter, and its loss of function leads to reduced bicarbonate concentrations in the air-
surface liquid, it may help explain the diminished activity of  endogenous host defense 
systems observed in CF lung infections (41–43). 
Following the bactericidal assays, we investigated whether the ability of CATH-2 
to modulate inflammatory responses by killed bacteria was maintained after suspension in 
the exogenous surfactant BLES. Two of the CF-isolated bacteria were killed ex vivo by 
heat, before intratracheal administration. This specific experimental procedure was utilized 
to specifically focus on the immunomodulatory properties of BLES+CATH-2 in response 
to the bacterial products from clinical strains of bacteria. The data obtained provided 
evidence that BLES+CATH-2 was capable of down-regulating inflammatory responses 
induced by killed bacteria, and that the immunomodulatory activity occurred via an 
antimicrobial-independent mechanism. This data is consistent with previous observations 
obtained with CATH-2 alone utilizing a non-clinical strain of P. aeruginosa presented in 
Chapter 3. The induction of inflammatory responses by heat-killed P. aeruginosa was 
shown to be completely mitigated after co-treatment with BLES+CATH-2, as shown by 
significant reductions in neutrophil influx, as well as reductions in all inflammatory 
cytokines investigated, including KC (mouse analog of CXCL1) and MIP-2 (mouse analog 
of CXCL2). This ability to not only kill clinically isolated antibiotic resistant bacteria, but 
to also diminish the inflammatory response after killing provides a unique multi-functional 
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therapeutic that would target two disease processes that are detrimental to CF patients (11, 
32, 41, 42, 44). 
Despite the profound anti-inflammatory activity of BLES+CATH-2 against heat-
killed P. aeruginosa, the administration of identical concentrations of heat-killed S. aureus 
produced a markedly different inflammatory response after intratracheal administration. 
Heat-killed S. aureus administration lead to a significant increase in inflammatory cells in 
the lavage, while co-treatment with both CATH-2 and BLES+CATH-2 significantly 
reduced inflammatory cell infiltration, similar to results observed after administration of 
heat-killed P. aeruginosa. Despite the increased neutrophil influx, no changes in cytokine 
production induced by heat-killed S. aureus stimulation were observed. It is possible that 
our method of heat-killing the bacteria induced significant changes to the 
immunostimulatory products of S. aureus, such as lipoteichoic acid or the peptidoglycan 
layer, as the lack of cytokines produced in this setting is inconsistent with previous studies 
investigating TNF-α production by alveolar macrophages in vitro (45). An alternative 
explanation for the lack of cytokine production observed in this study may be due to the 
downregulation of virulence genes, including toxins and cell surface adhesion molecules, 
which is commonly observed in CF patient-derived S. aureus isolates, therefore eliciting a 
diminished inflammatory response (46–48). 
It should be noted that, while the heat-killed bacteria model of inflammation used 
is not entirely indicative of the clinical environment, we believe this to be a superior method 
compared to instillation of single bacterial endotoxins, such as isolated lipopolysaccharide, 
or other immune-stimulating bacterial toxins such as lipoteichoic acid, flagella, etc. This 
method of inflammatory stimulation can account for a more relevant immune response, as 
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it has previously been reported that the initial inflammatory response induced by heat-killed 
bacteria is qualitatively similar to the response induced by live bacteria (49). In addition, 
while many pathogen associated molecular patterns interact with specific pathogen- 
recognition receptors, whole bacteria will induce signalling and lead to changes in cytokine 
expression through multiple pathways simultaneously (50). In the context of the current 
experiment, this suggests that CATH-2, as well as BLES+CATH-2, has the ability to 
interfere with multiple mechanisms of immune stimulation by bacteria, rather than via 
blocking of one specific virulence factor (45, 49, 51, 52).   
The use of exogenous surfactant as a vehicle to spread therapeutics throughout the 
lung has been explored extensively, including the delivery of conventional antibiotics (27–
29, 53–56). It has the ability to increase therapeutic concentrations deposited in the airways 
compared to aerosolized administration, as there is more uniform distribution and less 
material lost in the central conducting airway regions during administration (26, 57). 
Importantly, it also has the ability to bypass systemic administration, and reduces side 
effects often associated with high circulating concentrations of antibiotics (58). For 
cathelicidin peptides, this route of administration is especially important because of the 
relatively short half life of most peptides (59, 60). While previous studies have 
demonstrated that CATH-2 retains the most antimicrobial activity after suspension in the 
exogenous surfactant BLES compared to other peptides (30), there are no studies 
investigating the immunomodulatory activity of other cathelicidin peptides in BLES. If the 
immunomodulatory activity is retained, despite antimicrobial activity loss, the cathelicidin 
peptide library may become a crucial source for developing anti-inflammatory therapies 
for respiratory disease, and warrants further investigation. 
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In conclusion, we showed that the chicken cathelicidin CATH-2, in combination 
with the exogenous surfactant BLES, possessed bactericidal activity against clinically-
derived antibiotic-resistant CF pathogens in vitro. In addition to this, we showed that 
BLES+CATH-2 was able to downregulate inflammation through antimicrobial-
independent mechanisms by silencing the inflammatory response induced by killed 
bacteria. Taken together, the ability to kill multi-drug resistant bacteria and while being 
able to modulate the hyper-inflammatory environment induced by these pathogens within 
the CF patient airways provides strong evidence for the potential of BLES+CATH-2 as a 
therapeutic for the management of respiratory infections associated with cystic fibrosis. 
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Chapter 5: Efficacy of BLES+CATH-2 therapeutic 
administration in in vivo models of bacterial pneumonia 
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5.1 Introduction 
 Bacterial infection of the lungs, known as bacterial pneumonia, is the leading cause 
of mortality due to bacterial infection, accounting for 35% of all deaths due to infectious 
disease (1–3). While not always severe, approximately 24.8 cases per 10 000 adults with 
community acquired pneumonia will be placed in intensive care units, with 6% of those 
patients requiring mechanical ventilation (4). Pseudomonas aeruginosa is a common 
bacterial pathogen associated with respiratory tract infection in immunocompromised 
patients (5, 6). It is the second-leading cause of ventilator-associated pneumonia (VAP) 
worldwide, and is associated with mortality rates as high as 90% after infection of 
mechanically ventilated patients (7–10). Prevalence of antibiotic resistant infections has 
been steadily increasing, with between 40-82% of hospital-acquired bacterial pneumonia 
cases being caused by drug resistant infections (8). Indeed, P. aeruginosa resistance rates 
are not exempt from this trend. The prevalence of multi-drug resistant and extensively drug 
resistant isolates have steadily increased, and the rate of P. aeruginosa resistance towards 
carbapenems, a class of “last resort” drugs, has significantly increased over the past decade, 
with 34% of VAP isolates resistant to meropenem (10, 11). New treatment options are 
desperately needed.   
 To develop a new therapy for the treatment of P. aeruginosa pneumonia, previous 
work has identified a cathelicidin/surfactant combination that has shown effective 
combined activity - specifically, the chicken cathelicidin CATH-2 in conjunction with 
bovine lipid-extract surfactant (BLES). CATH-2 is one peptide that has been shown to 
possess potent antimicrobial activity, and unlike many cathelicidins, is able to maintain this 
activity in physiologically relevant salt conditions (12, 13). When suspended in BLES, 
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BLES+CATH-2 has shown enhanced adsorptive and spreading properties compared to the 
surfactant alone, whilst retaining the best bactericidal activity of all peptide/surfactant 
combinations investigated as demonstrated in Chapter 2 (14). Chapter 4 presents 
evidence of the therapeutic potential of this compound’s ability to kill multi-drug resistant 
bacteria. However, BLES+CATH-2 activity in vivo has yet to be investigated. In this 
chapter, we hypothesize that treatment with BLES+CATH-2 in animal models of bacterial 
pneumonia will improve physiologic outcomes and increase bacterial clearance from the 
airways.  
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5.2 Materials and Methods 
Bacterial Preparation 
An overnight culture of P. aeruginosa ATCC 27853 was diluted 1/10 before optical 
density was measured. The bacteria were then further diluted in either sterile saline for 
mouse experimentation, or Müeller-Hinton Broth (MHB) for rat experiments, in order to 
reach the initial concentration required for each individual experiment.   
 
In vivo treatment of acute bacterial pneumonia 
Male C57Bl/6 mice (Charles River, Sherbrooke, Qc, Canada), weighing 19-28 g, 
were used for this experiment. All animal procedures were approved by the Animal Use 
Subcommittee at the University of Western Ontario, and followed the approved guidelines 
described by the Canadian Council of Animal Care. Mice were anesthetized by 
intraperitoneal injection of ketamine (100-125 mg/kg body weight) and dexmedetomidine 
(0.5 mg/kg BW), and then intratracheally intubated using a 20 G catheter, with the aid of a 
fiber-optic stylet (BioLite intubation system for small rodents, BioTex, Inc., Houston, 
Texas, USA). Once intubated, mice were infected with 50 µl of bacteria at a concentration 
of 2x106 CFU/ml. Five minutes after bacterial administration, the mice were administered 
50 µl of one of the following five treatments: a) air bolus; b) saline; c) BLES (20 mg 
phospholipid/kgBW); d) CATH-2 (100 µM; 0.64 mg/kgBW); or e) BLES+CATH-2.  Mice 
were extubated following successful instillation and were subsequently injected with the 
reversal agent for dexmedetomidine, Antisedan, and allowed to breathe spontaneously for 
either four or eighteen hours. After, the mice were euthanized by IP injection of sodium 
pentobarbital (110 mg/kgBW) and dissection of the descending aorta. The lungs were 
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removed en bloc, and placed in 3 ml of sterile saline before homogenization using a Potter-
Elvehjam homogenizer. Aliquots from the homogenized tissue were plated on modified 
cetrimide agar plates, and colony enumeration was performed the following morning. 
 
In vivo rat ventilator-associated pneumonia model 
 Sprague-Dawley rats (Charles River, Sherbrooke, QC, Canada) weighing between 
330-435 g were used for this experiment. In brief, animals were anesthetized with a mixture 
of ketamine:dexmedetomidine (80 mg/kgBW; 0.5 mg/kgBW). Once no toe-pinch response 
was observed in the animals, they received a subcutaneous injection of the analgesic 
buprenorphine (0.05 mg/kgBW), followed by an additional subcutaneous injection of 
sensorcaine (bupivacaine HCL, 0.2 ml – 2.5%) in the ventral neck region at the site of 
incision. The right and left jugular veins were exposed and catheterized with PE-50 tubing 
in order to continuously infuse anesthetic (propofol, 5-20 mg/h), the neuromuscular blocker 
Nimbex (cisatracurium besilate, 0.4 mg/hr), and sterile fluids (heparinized saline 1000 
IU/l). One carotid artery was also exposed and catheterized in order to monitor heart rate, 
blood pressure, and blood oxygenation levels, as well as allowing for additional sterile 
fluids infusion. The trachea was then exposed, and intubated using a 14 G endotracheal 
tube and secured using 2-0 ligatures. After recording initial hemodynamic measurements, 
the rats were administered a bolus of Nimbex (0.4 mg/kgBW) and immediately placed on 
a volume-cycled rodent ventilator (Harvard Instruments, St. Laurent, QC, Canada). 
Mechanical ventilation was performed using 100% oxygen and a ventilation strategy that 
was set at a tidal volume of 8 ml/kg BW, a respiratory rate of 54-60 bpm, and a positive-
end expiratory pressure of 5 cmH2O.   
156 
 
 
 
 Throughout mechanical ventilation, airway pressures were monitored every 15 
minutes using an airway pressure monitor (Sechrist Industries, Anaheim, USA), and blood 
gas measurements were performed by ABL800. Fifteen minutes after being placed on 
ventilation, a blood gas was collected as a baseline. Inclusion criteria required an arterial 
oxygenation of 400 mmHg partial pressure of oxygen/fraction of inspired oxygen 
(PaO2/FiO2). 
 After reaching inclusion criteria, the animals were infected intratracheally with P. 
aeruginosa. As noted above, bacteria were diluted in MHB to reach an initial concentration 
of ~1x109 CFU/ml, of which 500 µl was instilled intratracheally. After instillation, the 
animals received 3 ml air bolus followed by a single breath-hold in order to optimize 
bacterial distribution throughout the airways. The animals were then returned to mechanical 
ventilation for one hour, with monitoring of hemodynamics and arterial blood gases. At 
this time, the animals were briefly disconnected from the ventilator and randomized to 
receive one of the following treatments: a) saline; b) BLES (20 mg phospholipid/kgBW); 
c) CATH-2 (100 µM; 0.64 mg/kg BW); or d) BLES+CATH-2. After instillation, the 
animals received 3 ml air bolus followed by a breath hold, similar to post-bacterial 
instillation, and returned to the ventilator and monitored for three hours. At the end of 
ventilation, the animals were euthanized by administration of a bolus of sodium 
pentobarbital (110 mg/kgBW) via the catheterized jugular vein, followed by dissection of 
the descending aorta.   
From one cohort, the lungs, spleen, liver, and blood were collected for 
homogenization. Tissues were suspended in various volumes of sterile saline (2 ml for 
spleen, 3 ml for lung, and 10 ml for liver tissue) and homogenized using a Potter-Elvehjem 
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homogenizing potter. The homogenate was then serially diluted and plated on cetrimide 
agar plates and incubated overnight before performing colony enumeration the following 
day. 
In the second cohort, bronchoalveolar lavage fluid (BALF) was collected via whole 
lung lavage as previously described (15). A sample of the BALF was serially diluted and 
plated on cetrimide agar plates in order to perform colony enumeration. The remaining 
BALF was then centrifuged at 150 g for 10 minutes. Supernatant was aliquoted for protein 
content analysis and inflammatory cytokine concentrations. The remaining cell pellet was 
suspended in 1 ml of PlasmaLyte, and diluted 100x. An aliquot of the diluted cell pellet 
was mixed with an equal volume of trypan blue in order to perform total cell counts using 
a hemocytometer and light microscopy.  In addition, a 10x dilution of the cell pellets were 
centrifuged onto cytospin slides at 1000 rpm for six minutes before staining with 
Hemacolor stain (Harleco, EMD Chemicals Inc., Gibbstown, NJ, USA). Cell differentials 
were then performed under light microscopy as previously described (16).  Protein content 
within the lavage fluid was determined using a Micro-BCA protein kit (Pierce, Rockford, 
IL) according to the manufacturer’s instructions. IL-6 and TNF-α levels were measured 
using respective enzyme-linked immunosorbent assay kits (ELISA kits; BD Biosciences, 
San Diego, CA, USA) according to the manufacturer’s instructions. 
 
Statistical Analysis 
 Statistical significance for the bactericidal activity of the various treatments in vivo 
was determined using a one-way measure analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test. The effect of various treatments on peak inspiratory pressures and 
158 
 
 
 
arterial oxygenation was assessed using a two-way ANOVA followed by Tukey’s post-hoc 
test. Total cell counts, cell differentials, and inflammatory cytokine concentrations were 
also analyzed by one-way ANOVA. Means are reported ± standard errors of the mean, and 
values were determined to be significantly different at a probability value (p) < 0.05. 
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5.3 Results 
Bacterial recovery in mice 
 After intratracheal inoculation of ~2x106 CFU/ml of P. aeruginosa ATCC 27853, 
mice were treated with a 50 µl intratracheal instillation of either CATH-2 (100 µM) or 
BLES+CATH-2 (20 mg/kgBW phospholipid; 100 µM). Four hours after treatment, 
bacterial recovery was significantly reduced from lung homogenate of animals treated with 
BLES+CATH-2 compared to saline controls (Figure 5.1a). CATH-2 treatment alone 
showed no significant effect on bacterial load in lung homogenate. 
 After 18 hours, all control treatment groups had a reduced bacterial recovery from 
the lung homogenate, indicating bacterial clearance by the animals’ innate immune defense 
system. The effect of BLES+CATH-2 administration was no longer observed 18 hours after 
instillation, as there was no significant difference in bacterial recovery from lung 
homogenate in animals treated with BLES+CATH-2 compared to any of the control 
treatment groups (Figure 5.1b). In contrast, lung homogenate from animals administered 
CATH-2 had a significantly increased bacterial load compared to all other treatment 
groups. 
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Figure 5.1 
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Figure 5.1. Bacterial recovery from lung tissue homogenate a) four hours, or b) eighteen 
hours after administration of P. aeruginosa. (n=5-8) *p < 0.05 vs. saline treatment; +p < 
0.05 vs. all treatment groups. 
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Physiologic outcomes in ventilator-associated pneumonia model 
 In the rat VAP model, the animals were placed on mechanical ventilation using a 
clinically relevant ventilation strategy (8 ml/kg BW tidal volume; 5 cmH2O positive end 
expiratory pressure, 54-60 breaths per minute respiratory rate). After reaching inclusion 
criteria of PaO2/FiO2 > 400 mmHg, the animals were inoculated with ~ 5x10
8 CFU of P. 
aeruginosa ATCC 27853. One hour following bacterial administration, the animals were 
administered treatments, and returned to the ventilator for three hours. Throughout 
ventilation, peak airway pressure was recorded. Saline-treated animals showed a significant 
increase in peak-inspiratory pressure (PIP) over the course of ventilation, indicative of 
decreasing lung compliance and development of lung injury (Figure 5.2). CATH-2 
instillation elicited a significant increase in PIP 15 minutes after instillation compared to 
BLES alone, with no other significant differences observed. Similarly, CATH-2 treated 
animals had significantly higher PIP values from 180 – 225-minute ventilation time points 
compared to BLES+CATH-2. 
 In addition, arterial oxygenation was also measured over the course of ventilation. 
For saline control treated animals, arterial oxygenation at the end of ventilation was reduced 
compared to baseline measurements, with the mean oxygenation decreasing to 199 mmHg 
by the end of ventilation, again indicating respiratory dysfunction (Figure 5.3). Animals 
that received CATH-2 treatment presented a significant, severe drop in arterial oxygenation 
immediately after administration (t60mins = 508.7 ± 15.12 mmHg; t75mins = 112.0 ± 16.73 
mmHg). Arterial oxygenation at this time-point was significantly different to every other 
treatment group, and CATH-2 treated animals showed significantly reduced oxygenation 
compared to BLES treated animals throughout the remaining three hours of ventilation.   
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 After treatment, BLES+CATH-2-treated animals also showed a significant increase 
in arterial oxygenation compared to CATH-2 treated animals throughout the course of 
ventilation. However, there was no significant difference between BLES+CATH-2 
treatment and either saline or BLES treatment (Figure 5.3). There was no significant 
difference in mean arterial pressure, heart rate, or the arterial partial pressure of carbon 
dioxide at any time point between any of the treatment groups. There was a significant 
reduction of pH in animals receiving CATH-2 alone compared to all other treatment groups 
at t = 75 mins (Table 5.1). 
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Figure 5.2 
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Figure 5.2. Peak inspiratory pressure over the duration of ventilation. (n=17-18) xxp < 0.01 
vs. BLES; +p < 0.05 vs. BLES+CATH-2. 
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Figure 5.3 
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Figure 5.3. Arterial oxygenation during mechanical ventilation.  Bacterial instillation at t 
= 0, treatment instillation at t = 60 min. (n=17-18) ***p < 0.001 vs. Saline; xp < 0.05, xxp 
< 0.01, xxxp < 0.001 vs. BLES; ##p < 0.01, ###p < 0.001 vs. CATH-2. 
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Treatment Group Baseline t=15 t=75 t=240 
Mean Arterial Pressure (mmHg) 
Saline 168.9 ± 6.78 110 ± 5.60 90.8 ± 5.41 53.5 ± 2.60 
BLES 161.9 ± 4.60 112.6 ± 6.39 83.7 ± 6.16 47.82 ± 3.74 
CATH-2 161.2 ± 4.89 115.2 ± 3.63 73.4 ± 2.92 45.6 ± 3.74 
BLES+CATH-2 168.8 ± 4.04 109.0 ± 5.41 81.78 ± 4.64 51.0 ± 3.08 
Heart Rate (bpm) 
Saline 248.9 ± 5.13 253.0 ± 4.19 232.4 ± 5.13 252.5 ± 6.02 
BLES 238.9 ± 5.58 252.4 ± 7.32 223.6 ± 7.32 252.2 ± 8.19 
CATH-2 241.7 ± 6.75 256.3 ± 2.99 218.1 ± 6.86 255.2 ± 8.19 
BLES+CATH-2 243.2 ± 5.23 250.8 ± 4.98 220.0 ± 5.38 249.9 ± 6.83 
PaCO2 (mmHg) 
Saline 45.07 ± 1.52 49.78 ± 1.34 51.24 ± 1.79 62.40 ± 3.48 
BLES 44.90 ± 2.08 48.39 ± 1.73 51.15 ± 2.26 58.09 ± 4.42 
CATH-2 43.80 ± 1.75 48.94 ± 1.77 57.09 ± 2.50 65.33 ± 4.81 
BLES+CATH-2 43.76 ± 1.50 49.22 ± 1.70 50.12 ± 1.30 56.66 ± 2.03 
pH 
Saline 7.356 ± 0.001 7.312 ± 0.010 7.271 ± 0.009 7.122 ± 0.017 
BLES 7.349 ± 0.012 7.314 ± 0.011 7.273 ± 0.012 7.136 ± 0.022 
CATH-2 7.359 ± 0.011 7.313 ± 0.008 7.227 ± 0.014* 7.107 ± 0.018 
BLES+CATH-2 7.350 ± 0.011 7.312 ± 0.011 7.276 ± 0.010 7.154 ± 0.012 
 
Table 5.1. Physiologic measurements of rats through duration of mechanical ventilation. 
(n=17-18) *p < 0.05 vs. all treatment groups. 
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Bacterial Clearance and Immune Response 
There was no significant difference in bacterial recovery between any treatment 
group in both the whole lung homogenate (Figure 5.4a) or from the BALF (Figure 5.4b). 
No significant difference in bacterial recovery was observed for any other tissues 
investigated, such as spleen, liver, or serum (data not shown). Total cells recovered from 
the BALF were not significantly different between treatment groups (Figure 5.5a). From 
the total cells, the majority of cell types (>90%) recovered from all treatment groups were 
neutrophils, however there was no significant difference in percentage of neutrophils 
between any treatment groups (Figure 5.5b). There was no significant difference in total 
protein content recovered from the BALF of any treatment group (Figure 5.5c). Cytokine 
analysis from recovered BALF fluid also showed no significant difference in TNF-α 
(Figure 5.5d). 
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Figure 5.4 
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Figure 5.4.  Bacterial recovery from a) lung tissue homogenate (n=9-11), or b) whole lung 
BALF after ventilation (n=6-7). 
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Figure 5.5. 
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Figure 5.5. a) Total cell counts recovered from whole lung BALF, and b) percentage of 
neutrophils from recovered cells. c) Total protein content recovered from BALF. d) TNF-
α content recovered from BALF. (n=4-7) 
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5.4 Discussion 
This study investigated the in vivo efficacy of BLES+CATH-2 as a treatment for 
bacterial pneumonia. Two animal models were investigated in order to determine 
BLES+CATH-2 bactericidal function against the clinically relevant pathogen P. 
aeruginosa. In our spontaneously breathing mouse model, BLES+CATH-2 was able to 
significantly reduce bacterial load from lung tissue four hours after intervention compared 
to saline controls, although this significant difference was no longer observed 18 hours after 
treatment. However, this bactericidal activity was not observed in the ventilator-associated 
pneumonia rat model, as BLES+CATH-2 had no effect on bacterial recovery from the lung 
tissue or bronchoalveolar lavage fluid. In addition, BLES+CATH-2 showed no significant 
improvement in arterial oxygenation at the end of ventilation. Taken together, these results 
demonstrate limited efficacy of BLES+CATH-2 after in vivo administration. 
 The rationale for this study was based in part on work described in Chapter 2, 
which investigated the in vitro properties of the exogenous surfactant BLES with a panel 
of different antimicrobial peptides (14). Throughout in vitro assays, it was identified that 
the cathelicidin peptides interacted differently with BLES, and therefore activity was 
modified as well. The most striking differences between peptides was their bactericidal 
activity in vitro, where despite potent antibacterial activity of all four peptides, the addition 
of BLES to mCRAMP and LL-37 completely abrogated all bactericidal function. On the 
other hand, while CATH-2 activity was mitigated, it showed the greatest bactericidal 
activity after suspension in BLES, and was therefore the most promising candidate for 
investigating its in vivo bactericidal efficacy. 
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 Despite a plethora of studies to suggest bactericidal efficacy of cathelicidins in vitro, 
data suggesting in vivo bactericidal activity is sparse (17, 18). Similar experimental models 
using different cathelicidin peptides have previously failed to show any therapeutic benefit 
(19). Other groups suggest that most cathelicidins, specifically LL-37 or mCRAMP, exert 
their therapeutic role through the recruitment of neutrophils, and that the direct bactericidal 
function of these peptides in negligible in vivo (20). It has been hypothesized that 
environmental conditions and/or the short half-life of cathelicidins are responsible for this 
lack of direct bactericidal activity in vivo (19, 21). In this study, we provide evidence that 
BLES+CATH-2 may be able to exert some bactericidal activity, as shown through the 
reduction in bacterial recovery from lung homogenate.  
Previous studies performed in both Chapter 2 and Chapter 4 provided convincing 
evidence of CATH-2 bactericidal potential in vitro, and moreover, that the addition of 
BLES would actively reduce this antimicrobial activity. However, observations from this 
study suggest that the bactericidal activity of CATH-2 and BLES+CATH-2 are much less 
clear, as in our mouse pneumonia model, we observed a marginal decrease in bacterial 
recovery from animals administered BLES+CATH-2, that was not observed from CATH-
2 treatment alone. This may in fact be due to the improved distribution and increase site 
concentrations in these infection models, as hypothesized by the use of an exogenous 
surfactant vehicle. The use of exogenous surfactant as a vehicle to spread therapeutics 
throughout the lung has been explored extensively using conventional antibiotics (22–28). 
Studies have shown that the use of exogenous surfactant as a vehicle has the potential to 
increase the delivery efficiency of therapeutics to the lung over parenteral or intravenous 
therapy (22, 26, 29–31). The four-hour acute pneumonia studies provide some evidence to 
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suggest that BLES may be increasing the distribution of CATH-2 to the infection sites. 
However, it appears that this increased spreading is not sufficient to significantly improve 
bactericidal activity, as both the 18-hour pneumonia model and the VAP model showed no 
reduction in bacterial recovery. 
Expanding on the well-studied antimicrobial and immunomodulatory activity 
throughout this thesis, this chapter also investigated the ability of BLES+CATH-2 to 
improve arterial oxygenation, a clinically relevant outcome for patients placed on 
mechanical ventilation (32). This study provides evidence that BLES+CATH-2 can 
mediate a small improvement in arterial oxygenation, as animals administered 
BLES+CATH-2 had an average increase of 77 mmHg compared to saline treated animals, 
although this was not statistically significant. Additionally, this effect was also observed 
by BLES treatment alone, which also improved oxygenation an average of 64 mmHg by 
240 minutes, but again was not statistically significant. This data lends some support to the 
hypothesis that the use of BLES can distribute throughout the lungs and into small 
peripheral airways and alveoli, as previous work has suggested that this exogenous 
surfactant administration is directly related to improved oxygenation (31, 33). 
While both BLES and BLES+CATH-2 were able induce a mild improvement in 
arterial oxygenation, CATH-2 treatment alone showed a significant deleterious effect. This 
effect was most clearly observed in the VAP model, where despite a mild reduction in 
bacterial recovery, CATH-2 administration caused a rapid and severe decrease in 
oxygenation. This decrease was statistically lower than all other treatment groups between 
time point 75 mins (immediately after treatment instillation) until the end of the ventilation 
protocol. It is hypothesized that this drastic reduction is due to cytotoxic activity of CATH-
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2, leading to diffuse airway damage and decreasing oxygenation. The cytotoxic activity of 
CATH-2 has been demonstrated in vitro via hemolytic assays, and we theorize that this 
activity is the cause of the rapid decline in oxygenation (13). We expect that this is also the 
reason behind the increased bacterial recovery observed at 18 hours in the mouse, where 
increased epithelial damage would improve bacterial colonization and proliferation. 
However, we could not detect any differences in protein content or inflammatory cytokines 
within the BALF, which would be expected in the case of severe epithelial cell death, and 
therefore further studies to confirm these observations are required. Importantly, 
BLES+CATH-2 administration did not induce any of these deleterious changes, indicating 
greater safety and tolerability of administration, even though data supporting any 
therapeutic benefit is currently lacking. 
As mentioned, this chapter is the first investigation of direct bactericidal activity, 
and ability to affect clinically relevant outcomes, in two separate in vivo animal models. In 
this chapter, we utilized a well-described model of acute bacterial pneumonia in a C57Bl/6 
mouse, and a rat VAP model using Sprague-Dawley rats. The mouse model investigated 
here has previously been used to study the effect of exogenous cathelicidin administration 
for the treatment of P. aeruginosa respiratory infection (20). However, whereas previous 
studies collected BALF and measured cell recruitment and cytokine production, our initial 
studies solely investigated bacterial recovery, and were therefore limited by the use of 
tissue homogenate instead of lavage fluid analysis. In order to expand on these initial 
studies, the VAP-rat was used to collect and analyze both tissue homogenate and BALF 
rather than the mouse pneumonia model. This second model was selected for two reasons: 
1) a significantly greater volume of BALF is available in rats, and 2) we are able to measure 
174 
 
 
 
peak-inspiratory pressure, arterial oxygenation, and a number of other clinically-relevant 
parameters in the VAP model that were unavailable in the mouse pneumonia model. Thus, 
the inclusion of the VAP model permitted a greater range of outcome measurements. In 
addition, this study provided the opportunity to investigate the therapeutic potential of 
BLES+CATH-2 in severe lung dysfunction and inflammation settings, as noted by 
decreased oxygenation, and increased inflammatory cytokine production. Taken together, 
these two models were able to provide substantial data towards the efficacy of 
BLES+CATH-2 treatment in separate in vivo pneumonia models. 
However, despite the large amount of data acquired from these models, there are 
many limitations of study. The first issue involves the use of P. aeruginosa as our bacterial 
model of infection. It has been well documented that, in healthy animal models, P. 
aeruginosa can be readily cleared by the host immune system (34). This is the likely 
explanation for why there was such a large reduction in bacterial recovery 18 hours after 
administration in the mouse pneumonia model regardless of treatment. Similar limitations 
were observed in the rat VAP model, as rats clear P. aeruginosa even more efficiently than 
mice (34). To this effect, preliminary studies performed in collaboration with Dr. Nicholson 
identified the bacterial load required to develop a respiratory infection that caused a 
significant reduction in arterial oxygenation over the course of ventilation, without the 
innate clearance of the bacteria. The resulting data suggested that the rat VAP model 
required a much larger bacterial load to develop signs of lung injury during infection than 
the acute pneumonia model used in mice. It is possible that this large dose was the reason 
why no bactericidal activity of BLES+CATH-2 was observed in this model, a phenomena 
known as the “inoculum effect”, in which antibiotics lose potency as bacterial load 
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increases (35). In future, animal models should utilize different strategies for infection, in 
order to more accurately model development of bacterial pneumonia. Use of different 
animal/bacteria combinations, would better describe the progression of a respiratory 
infection and development of chronic disease states, which more accurately represents the 
situation in clinical settings and would better predict the efficacy of therapeutic treatments 
against these infections (10, 36–40). Animal models that are administered multiple 
therapeutic doses would also be more viable for future testing, as again these would be 
more accurate of the treatment regimens currently prescribed (41–44). 
In conclusion, this study presented evidence that BLES+CATH-2 can exhibit some 
bactericidal activity in vivo as observed in the mouse model of acute bacterial pneumonia, 
which showed a significant reduction in bacterial recovery four hours after instillation 
compared to control treatments, and lead to a mild improvement in oxygenation in VAP 
models compared to saline controls, although there was no statistically significant 
difference between these treatment groups. Moreover, while CATH-2 appeared to induce 
detrimental effects after administration, none of the negative outcomes were observed after 
BLES+CATH-2 treatment, suggesting safety and tolerability of this compound. While we 
were unable to identify any statistically significant improvement to clinical outcomes in 
both of our infection models, this was the first study to investigate the activity of 
BLES+CATH-2 in vivo, and supports the conclusions that BLES+CATH-2 does not induce 
harmful side effects after administration. Future studies will be required in order to improve 
BLES+CATH-2 therapeutic activity in vivo, via increased bacterial clearance and improved 
arterial oxygenation, without sacrificing compound tolerability. 
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Chapter 6: Summary and discussion of major findings 
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 The objective of this thesis was to develop and investigate the therapeutic potential 
of a cathelicidin peptide/exogenous surfactant compound mixture for the treatment of 
bacterial pneumonia. The high incidence of bacterial pneumonia, coupled with the 
increasing prevalence and global health crisis of multi-drug resistant infections, was the 
rationale for our pursuit of therapeutic development (1, 2).  
 Our hypothesis was that the use of cathelicidin peptides (multifunctional peptides 
with potent antimicrobial activity and immunomodulatory properties) in combination with 
exogenous pulmonary surfactant (which is able to spread rapidly throughout the airways, 
with improved deposition compared to aerosol administration) would improve outcomes in 
bacterial pneumonia. Throughout this thesis, we developed and tested a 
cathelicidin/surfactant compound for it’s ability to a) maintain biophysical activity, b) 
provide antibacterial activity, c) modulate the inflammatory response during stimulation by 
dead bacteria, and finally d) investigating the antibacterial, immunomodulatory, and 
physiologic benefit of BLES+CATH-2 in in vivo models of pneumonia. 
Initially, we investigated the properties of various cathelicidins with the exogenous 
surfactant BLES to select an optimal cathelicidin/surfactant combination in Chapter 2. By 
investigating the biophysical properties of the surfactant with various cathelicidin peptides, 
we observed that the four cathelicidin peptides tested had minimal effect on biophysical 
function, i.e. the ability to reduce surface tension upon lateral compression. When 
investigating the adsorptive properties of these cathelicidin/surfactant combinations, we 
observed that cathelicidins enhanced diffusion in a dose-dependent manner. We theorized 
that this increased adsorption was caused by the cathelicidins’ ability to interact with and 
“break” the surfactant bilayers in the aqueous subphase, increasing surfactant material 
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released and available to move to the air-liquid interface. The surfactant protein SP-C, 
which is relatively similar to cathelicidins in structure, is crucial for surfactant adsorption 
(3, 4). It is possible that cathelicidins interact with the surfactant phospholipids through a 
similar mechanism, which would explain the phenomena observed in this thesis. 
In addition to these findings, we also discovered that bactericidal activity of 
cathelicidins was severely impaired when mixed with surfactant. Due to the cationic nature 
of cathelicidins, and the presence of anionic phospholipids, such as PG, we theorize that 
this reduced activity is due to electrostatic interactions of the peptides with PG, “masking” 
the cationic charge of the peptide and preventing the interaction with bacterial membranes. 
These results were verified when investigating BLES+CATH-2 activity against MDR-
isolates obtained from CF patients in Chapter 4. However, the degree of inhibition appears 
to be cathelicidin dependent; while CATH-2 and CATH-1 still maintained some 
bactericidal activity, LL-37 and mCRAMP completely lost antimicrobial functions. It is 
possible that, due to different peptide structures, different cathelicidin 
interactions/orientations within the phospholipid membranes may differ the charge 
masking, as previously observed (5–7). This would allow peptides such as CATH-2 (with 
two α-helical regions, both containing basic amino acid residues) to maintain some 
interaction with bacterial membranes, while other peptides (i.e. LL-37, with a single α-
helical region that spans the majority of the peptide) insert deeper inside the membrane, 
and completely mask antimicrobial activity. In all, the key conclusions to be drawn from 
these results is that a) BLES+CATH-2 shows the most potent bactericidal properties of all 
cathelicidin/surfactant combinations tested to date, and b) that this compound retains 
bactericidal activity against MDR-clinical isolates. 
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While BLES+CATH-2 showed the most potent bactericidal activity, the 
immunomodulatory activity of CATH-2, as well as BLES+CATH-2, was relatively 
unknown. Unpublished results from our lab, as well as from our collaborator Dr. Coorens 
at Utrecht University demonstrated that, in vitro, CATH-2 and BLES+CATH-2 were able 
to prevent pro-inflammatory cytokine production from macrophages after treatment with 
either LPS or killed bacteria. These studies are supported by a wealth of data about other 
cathelicidin peptides, which suggest that one of the endogenous functions of cathelicidins 
is to downregulate inflammatory signalling by bacterial toxins, such as LPS (8–11).  
To expand on this, Chapter 3 and Chapter 4 investigated whether CATH-2 and 
BLES+CATH-2 could provide this anti-inflammatory activity with killed bacteria in vivo. 
Instillation of heat-killed bacteria, which has previously been used to study inflammatory 
responses (12–14), were used to focus solely on CATH-2 immunomodulatory activity. The 
benefit of this model over instillation of a single bacterial PAMP (i.e. LPS or LTA) was the 
presence of multiple immunogenic compounds able to activate multiple different PAMP 
receptors and signalling pathways simultaneously. In these studies, the co-treatment of 
CATH-2 or BLES+CATH-2 with heat-killed P. aeruginosa, including both ATCC strains 
and MDR-clinical isolates, were able to reduce inflammatory cytokine production to 
concentrations equal to naïve and control treatment groups. These studies present evidence 
that CATH-2, and importantly BLES+CATH-2, can prevent and/or reduce the 
inflammation elicited by killed bacteria. 
On top of the ability of CATH-2/BLES+CATH-2 to modulate inflammatory 
responses, Chapter 3 demonstrated that bacteria killed by CATH-2 did not induce any 
inflammatory response. This activity, termed “silent killing”, was initially presented by Dr. 
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Coorens in vitro, and showed that the cathelicidin peptide CATH-2 was able to kill bacteria 
in co-cultures with macrophages without inducing an inflammatory response (15). These 
results were expanded to the in vivo setting, which demonstrated that CATH-2-killed 
bacteria did not induce an inflammatory response in the airways after intratracheal 
instillation. Animals that received CATH-2-killed bacteria, similar to heat-killed bacteria 
co-treated with CATH-2 or BLES+CATH-2, has less inflammatory cells recovered from 
the BALF, and reduced cytokine concentrations in BALF. This “silent” killing mechanism 
has vast therapeutic potential moving forward, as the ability to kill bacteria without eliciting 
an inflammatory response would greatly increase recovery time, and limit the collateral 
tissue damage caused by inflammatory cell migration and activation. 
However, treatment of VAP with BLES+CATH-2 showed no beneficial effects in 
Chapter 5. Indeed, while treatment in the mouse acute pneumonia model showed a 
significant difference between saline-controls and BLES+CATH-2 treatment, this 
bactericidal activity was not observed in the rat VAP model. While treatment with 
BLES+CATH-2 significantly increased oxygenation in this model compared to CATH-2 
alone, there was no significant improvement over saline or BLES controls. In all, it appears 
that BLES+CATH-2 was an ineffective therapeutic for P. aeruginosa induced VAP in our 
rat model. 
Based on the data accumulated throughout this thesis project, we conclude that 
BLES+CATH-2 has some therapeutic potential for the treatment of multi-drug resistant 
bacterial pneumonia. However, the lack of antimicrobial activity demonstrated in vivo 
suggests that further research is needed in order to improve BLES+CATH-2 activity. The 
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purpose of this chapter is to discuss potential future directions in order to continue 
development and improve the efficacy of BLES+CATH-2 as a therapeutic compound. 
 
6.1 Future Directions 
6.1.1 Alterations to exogenous surfactant composition 
 As described in Chapter 2, we theorize that the cause of the mitigated bactericidal 
activity of BLES+CATH-2 involves the electrostatic interactions between the highly 
cationic CATH-2 and anionic phospholipid PG in BLES. As such, one method to improve 
the bactericidal activity of BLES+CATH-2 would be to reduce the content of anionic 
phospholipids in the surfactant, freeing more cathelicidin peptide to interact with bacterial 
membrane.  
 Previous work has gone into great detail over the orientation of cathelicidin peptides 
in lipid membranes with different phospholipid content (5–7). From this, and from our 
observations with cathelicidin peptides and the exogenous surfactant BLES, we 
hypothesize that a reduction in PG content would reduce any electrostatic activity with the 
cathelicidin peptide, without sacrificing surfactant biophysical properties. Indeed, many 
natural surfactants and synthetic surfactants have varying phospholipid concentrations, 
with PG content ranging anywhere between 20% (15) to as low as 7% found in endogenous 
rabbit surfactant (16). By reducing the content of the acidic phospholipids in BLES from 
~10% to as low as 5-7%, we hypothesize that we would be able to increase natural 
cathelicidin activity (i.e. bactericidal function), without significant alterations to surfactant 
spreading or biophysical function. However, future testing is required to determine if this 
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hypothesis is correct, and if this would improve the therapeutic viability of a modified 
surfactant + CATH-2. 
 One experimental approach to investigate this would be to formulate a synthetic 
surfactant. With the addition of recombinant surfactant proteins, this synthetic surfactant 
could be produced with a specific phospholipid composition aimed at improving the 
interactions between the surfactant and the antimicrobial peptide to optimize antimicrobial 
and immunomodulatory functions in vivo. This new surfactant could then be re-investigated 
using the protocols described in this thesis to determine biophysical properties, 
antimicrobial activities, immunomodulatory functions, and in vivo efficacy. Using 
throughput screening of different surfactant compositions and cathelicidin peptides, we 
anticipate that a surfactant/cathelicidin compound could be identified and developed as a 
suitable therapeutic. 
 
6.1.2 Focus on development of anti-inflammatory therapeutic 
 In lieu of the strong anti-inflammatory activity shown by BLES+CATH-2 in 
Chapter 3 and Chapter 4, our lab has continued focus on investigating these properties of 
BLES+CATH-2. Unlike the antimicrobial activity, BLES+CATH-2 appears to exhibit 
much more consistent immunomodulatory activity. Work recently performed by an 
undergraduate student, Christina Arsenault, showed that both CATH-2 and BLES+CATH-
2 was able to downregulate inflammatory responses after co-administration with heat-killed 
P. aeruginosa, similar to results observed in Chapter 4. However, in addition, Ms. 
Arsenault showed that after a 15-minute delay in administration (i.e. instillation of 
treatment 15 minutes after instillation of heat-killed bacteria), CATH-2 lost its anti-
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inflammatory properties, while BLES+CATH-2 treated animals showed reduced 
inflammatory cytokine production and cell infiltration. 
In addition to this, more work done by a graduate student, Brandon Baer, has 
continued these investigations by re-visiting the combined therapy of CATH-2 and 
conventional antibiotics. Mr. Baer has identified that bacteria killed by a lower, more 
clinically relevant dose of gentamicin than what was used in Chapter 3 (8 µg/ml vs. 1 
mg/ml in Chapter 3) still elicit an inflammatory response similar to what was described in 
this thesis. However, unlike previous results, the addition of CATH-2 did once again reduce 
the production of inflammatory cytokines. Adding to the potential anti-inflammatory 
activity of CATH-2, Mr. Baer has revisited other cathelicidin peptides, including LL-37 
and PMAP-23, which showed that these anti-inflammatory properties appear to be 
relatively well conserved across multiple different peptides. 
This data, combined with the work performed by Ms. Arsenault, provides a 
rationale for investigating the immunomodulatory activity of different cathelicidin peptides 
with the exogenous surfactant BLES. The anti-inflammatory activities of cathelicidin 
peptides, when administered with antibiotic-killed bacteria, presents a unique avenue for 
therapeutic development in order to manage inflammation post-infection. In addition, the 
supplementation of BLES appears to have a significant therapeutic benefit to this 
immunomodulatory activity, and if this beneficial effect is conserved with other peptides, 
it would vastly increase the library of therapeutic agents available for clinical development 
and use. Therefore, there is a strong rationale to continue investigations into the 
immunomodulatory activity of different cathelicidin peptides/exogenous surfactant is to 
increase understanding of the therapeutic benefit of these compounds. The use of a various 
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animal models to investigate multiple different mechanisms of lung inflammation, such as 
asthma or chronic obstructive pulmonary disease, would allow for a thorough, robust 
investigation to the limits and potential of BLES+CATH-2 as a respiratory anti-
inflammatory treatment. 
 
6.2 Concluding Remarks 
The presence of multi-drug resistant infections is the largest global health concern 
facing this generation, and without the development of new therapies and practices, will 
become the leading cause of death worldwide by 2050 (2). The high prevalence of bacterial 
pneumonia, makes development of therapeutics specifically for respiratory tract infections 
especially important. 
Cathelicidin peptides are a unique source of development for future therapeutics for 
respiratory infections. Their combined microbicidal activities and immunomodulatory 
properties give these peptides a vast diversity of potential uses. The combined treatment 
strategy of a cathelicidin peptide with exogenous surfactant, ideal to spread the peptides 
throughout the complex lung structure, was investigated in this thesis. While the proof-of-
principle determined the validity of this approach in vitro, the lack of antimicrobial activity 
and physiologic improvements in in vivo models limits the potential of this compound. 
Instead, anti-inflammatory activity was much more well defined, and may represent another 
avenue for BLES+CATH-2 therapeutic development.  
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